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Section 1. Introduction 
1.1 The Burden of Acute Gouty Arthritis 
Acute Gouty Arthritis, or gout, is one of the most common rheumatologic diseases 
around the world, and the most prevalent form of inflammatory arthritis in the United States, 
affecting over eight million Americans.1 Characterized by moderate to severe pain, limited 
mobility, and chronic inflammation, gout is a debilitating condition with substantial implications 
for a patient’s quality of life.2,3 While gout is etiologically different from other rheumatologic 
diseases, it is clinically comparable to the disease burden associated with rheumatoid arthritis; 
however, while primary hospitalization rates for rheumatoid arthritis have decreased over the last 
ten years, annual hospitalizations for gout have doubled in the same timeframe.4 Moreover, 
despite the increase in both prevalence and incidence of gout around the world, suboptimal gout 
management persists.5,6  
Gout not only presents a substantial societal and personal burden, but a financial burden 
as well, with the care for this condition estimated at over $3,000 in additional costs annually per 
patient with gout.7 In a recent systematic review of the economic burden of gout, gout-related 
cost may range between $172 to $6,179 annually, with costs considerably greater among elderly 
and treatment-refractory gouty patients.8 However, factoring in the various co-morbidities 
associated with gout, the indirect costs likely exceed these estimates. 
The burden and risk of gout differs significantly by demographic characteristics, 
particularly age and sex.9 Gout is four times more prevalent in men under 65 years old compared 
to women within the same age range; however, after 65 years of age, this difference in 
proportion begins to decrease.10 A possible explanation for these trends is that estrogen facilitates 
an increase in uric acid clearance. As a result, menopause, which results in a dramatic decline in 
the production of estrogen, leads to a significantly higher risk of gout in women when compared 
to premenopausal women; this effect is  further exemplified by post-menopausal women using 
estrogen and progesterone, who have a significantly lower risk of gout compared to those not 
using these hormone replacement therapies.11  
As a condition strongly associated with the aging process, incident cases of gout are 
expected to increase in the coming decades, having already doubled over the past 20 years.6,11 
The World Health Organization projects a rapid increase in the world’s proportion of adults over 
60 years old in the next few decades, nearly doubling by 2050 from the most recent estimates.12 
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With cases on the rise, further investigation into the determinants of gout is crucial in assessing 
the personal, social, and economic burden in a globally aging population. Moreover, recent 
trends suggest an increasingly ethnically diverse older population, particularly in the US.13 
Understanding differences between populations remains a crucial gap in individualizing care for 
those affected by gout and other chronic health conditions. 
1.2 Etiology and Clinical Features of Gout and Hyperuricemia 
Gout is characterized by the accumulation of monosodium urate (MSU) crystals within 
joints from elevated uric acid levels, or hyperuricemia.6 Humans are the only known mammal 
that develops gout, while hyperuricemia is only found in other primates. Uric acid, the final 
product of purine catabolism, is the well-established causal component to the development of 
acute gout. Most organisms possess the enzyme uricase, which converts uric acid to the more 
soluble allantoic acid via oxidative degradation; however, due to mutational silencing events in 
the gene that encodes uricase, humans and great apes lack this enzyme, and thus, the less soluble 
uric acid is the final product in the breakdown of endogenous and exogenous purines.14 As a 
result, humans generally have higher uric acid levels than other mammals.  
Hyperuricemia may be caused by the overproduction of urate from purine catabolism, or 
its underexcretion by the renal system; most individuals who develop gout have issues with both 
overproduction and underexcretion, with underexcretion thought to be the more important 
contributor to the disease state.15,16 Recent genome-wide associations studies (GWAS) have led 
to the discovery of risk variants within genes related to the renal urate transport and subsequent 
excretion.17 For instance, SLC2A9, a gene that encodes a urate uniporter, was demonstrated as 
having a large effect on uric acid levels, especially among females.18 Similarly, ABCG2, a gene 
that encodes a transporter that mediates urate secretion, was found to explain up to 10% of gout 
cases among both Whites and Japanese.19,20 While these findings show that much of 
hyperuricemia may be attributable to genetic variation, lifestyle factors likely interact with 
genetics, and modify one’s risk of gout. 
While there exists little debate on whether gout is a severe and debilitating chronic 
condition, quantifying the disease burden at a population level depends on differing case 
definitions.11 The presence of MSU crystals in joint fluid, or the presence of detectable MSU 
deposits, is considered the gold standard in diagnosing gout.11 Unfortunately, the procedure for 
confirming gout under this criteria is invasive and often infeasible in practice, and thus, rarely 
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used to establish a diagnosis.21 Other techniques, including ultrasound, magnetic resonance 
imaging, and computer tomography, can be used to detect MSU crystals; however, these 
procedures can be both expensive and inconclusive.22 Therefore, most cases of gout are 
diagnosed by professional opinion, and as a result, varying and inconsistent operation 
characterizations create challenges in investigating the epidemiology of gout.23,24  
In general, clinical gout progresses through four stages: asymptomatic hyperuricemia, 
acute gouty arthritis, intercritical gout, and chronic tophaceous gout or advanced gout. 
Asymptomatic hyperuricemia is a condition where serum uric acid concentrations are elevated to 
>6.8 mg/dL, yet no detectable symptoms of gout are present.25 For this reason, asymptomatic 
hyperuricemia is sometimes not considered to be part of the disease state, but rather an early 
warning sign.16 Gouty flares characterize the acute phase of gout in which the uric acid 
concentration reaches its saturation threshold and begins to crystallize, depositing in joints, 
tendons, and related tissues, typically of the lower extremities.26 The MSU deposits, referred to 
as tophi, cause a sudden onset of pain, erythema, and limited range of motion, and trigger the 
inflammatory response.16 Most individuals living with asymptomatic hyperuricemia do not 
progress into acute gout; however, prior studies report that patients with urate concentrations 
exceeding 9.0 mg/dL are six times more likely to experience a gouty flare.27,28 Following a flare, 
patients enter an intercritical phase, where symptoms of gout are no longer present for up to 
several months or years, depending on treatment quality.29 When gout is left without or with 
improper treatment, intercritical periods become progressively shorter, and gouty flares become 
more severe and longer lasting.11 The final stage, advanced gout, is defined by intercritical 
periods no longer being pain-free. Because advanced gout is associated with the presence of 
destructive subcutaneous tophus nodules, it is sometimes referred to as chronic tophaceous gout; 
however, subcutaneous tophi are not always present or detectable during this phase. 
1.3 Modifiable Lifestyle Risk Factors 
From a historical perspective, gout is an ancient disease, and its association with 
modifiable lifestyle factors has long been recognized.16,30 As previously mentioned, gout is 
caused by both the overproduction and underexcretion of uric acid. Thus, behaviors that 
contribute to these two causal pathways may modify one’s risk and management of the disease.  
Perhaps one of the first, and most widely, established lifestyle factor is alcohol 
consumption. In a meta-analysis of alcohol use and risk of gout, researchers found an increased 
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risk among all levels of consumption, with a pooled relative risk (RR) of 2.64 (95% confidence 
interval [CI]: 2.26, 3.09) among heavy drinkers compared with non/occasional drinkers, across 
17 observational studies. Similarly, in a prospective cohort study of men from the Health 
Professionals Follow-up Study, alcohol intake increased the risk of gout incidence in a dose-
dependent gradient; beer consumption, in particular, had the strongest effect estimate (RR=1.49, 
95%CI: 1.32, 1.70, for one 12-ounce beer per day).31 Alcohol most likely contributes to both 
causal pathways of gout.11 Many alcohol beverages, namely beer, are purine-rich, and may 
increase uric acid production through the catabolism of common purines found in beer, such as 
guanosine.32 In addition, alcohol use may downregulate excretion of the resulting excess uric 
acid by producing lactic acid, which competitively inhibits uric acid secretion.33  
Much of the overproduction of uric acid may be attributed to the overconsumption of 
purine-rich foods, increasing one’s risk of gout. Foods with large amounts of purines include: 
meats, seafood, other sources of animal proteins, and certain vegetables.9 A 12-year prospective 
study of men reported that higher intake of meat and seafood were significantly associated with 
an increased risk of gout; however, risk of gout was not significantly predicted by purine-rich 
vegetable intake.34 One possible explanation for why purine-rich vegetables were not associated 
with gout might be that plant-based purines are less bioavailable than those found in meats.11 In 
the same aforementioned study, dairy products were found to lessen an individual’s risk of 
developing gout, possibly elucidating urate-lowering properties.34  
Similar to alcohol consumption, sugar sweetened beverages and fructose also may 
contribute to the risk of gout through a dual-pathway mechanism; fructose and sugar-sweetened 
beverages increase lactic acid levels, leading to a decreased ability to excrete uric acid.9 As such, 
a prospective cohort study found that consumption both of  sugar-sweetened beverages and 
fructose-rich foods were strongly associated with an increased risk of gout incidence among 
men.35 Moreover, several studies report interactions between polymorphisms within SLC2A9 
and ABCG2 and the handling of fructose and sugar-sweetened beverage intake, possibly further 
exacerbating the underexcretion pathway.36 
Finally, adiposity also may have a strong independent role in the development of both 
hyperuricemia and gout.11 In a systematic review and meta-analysis of ten prospective studies, 
greater body mass index (BMI) increased the risk of gout incidence in a dose-dependent manner 
using five-unit increment measurement, with a pooled RR of 1.55 (95%CI: 1.44, 1.66).37 
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Similarly, a large 7-year intervention trial found that weight-loss was strongly associated with a 
decrease in serum uric acid among men with a high cardiovascular risk profile, compared to 
those with no weight change.38 Researchers postulate that adiposity likely contributes to gout 
through both underexcretion and overproduction of uric acid.11 
1.4 Inflammation, Antioxidants, and Uric Acid 
Other factors may contribute negatively to gout incidence, possibility elucidating uric 
acid lowering or antioxidant properties, or through an attenuation of other risk factors. Some 
examples include coffee consumption39,40, supplementation41 and dietary intake42 of vitamin C, 
and the aforementioned dairy products. Little is known about how high levels of uric acid might 
interact with other antioxidants, especially considering gout-related inflammation.  
Uric acid plays a complex role in inflammation and subsequent oxidative stress, acting as 
a pro-inflammatory, and as both an anti-oxidant and a pro-oxidant.43 Findings from experimental 
and observational studies report a positive association between inflammatory biomarkers and 
uric acid, as well as a mechanistic role for uric acid in the reduction of oxidative stress.44,45 
However, some evidence suggests that C-reactive protein (CRP), a commonly used inflammation 
biomarker, might not be a sound indication of gout risk.46 Few have investigated the effects of 
smoking on gout; however, some suggest that smoking may decrease serum uric acid.47 Given 
this evidence, smoking cessation might lead to an increased risk of hyperuricemia and gout.9  
1.5 Ethno-Racial Disparities of Gout 
Racial and ethnic disparities in debilitating, and often preventable, chronic diseases are 
common, and pose important implications for an individual's risk, care, and prognosis. While 
historically a disease of affluent Europeans, recent findings from a multitude of large 
epidemiologic studies have reported marked racial/ethnic disparities in gout and hyperuricemia 
among groups already at an increased risk of morbidity and lack of access to high quality care. 
For example older African Americans, already at an increased risk of poor health care access and 
quality of care, have a significantly increased risk of developing gout compared to Whites.48,49 In 
a longitudinal study of African American and European American participants from the 
Atherosclerosis Risk in Communities Study, researchers found the African American 
participants had an increased risk of incident gout compared to European American participants 
among both men (Hazard Ratio [HR] =1.92, 95%CI: 1.44, 2.56) and women (HR=1.69, 95%CI: 
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1.29, 2.22), after adjusting for uric acid levels, BMI, diet, diabetes, hypertension, and diuretic 
use.50 
Aside from White and Black Americans, investigation into the prevalence and disparities 
among other racial/ethnic groups are scarce, with little to no investigation into the growing 
Hispanic populations in the United States.51 However, recent evidence suggests many Asian-
Pacific Islander groups may be at an increased risk of hyperuricemia and gout, including 
Filipinos, Micronesians, Maori, and various other Polynesian groups.15,52 Polynesians, 
particularly those of Austronesian decent, are reported as having the highest global prevalence of 
both acute gout and hyperuricemia.53 Moreover, while the prevalence is higher among males, 
prior studies report a higher risk of gout among Polynesian women, compared to their White 
counterparts.54 Despite the increased risk of gout within the Pacific region, there are few studies 
examining the determinants or impacts among these communities; however, some have 
attributed these disparities to the interaction between genetic predisposition and Westernization 
of indigenous lifestyle.9,53,55 Nonetheless, while genome-wide associations studies have 
demonstrated the influence of risk variants within some Asian-Pacific populations, particularly 
SLC2A9 and ABCG2 among the New Zealand Maori and Japanese, there does not appear to be 
differences in gout-related risk allele frequencies compared with Europeans.15,17,48,56,57 
1.6 Specific Aims and Hypotheses 
Given the disease burden, economic impact, and paucity of information, especially 
among underserved minority populations, further investigation into the ethno-racial disparities of 
gout incidence is warranted. Moreover, racial/ethnic-stratified examination into these 
associations may further elucidate differences in the effects of modifiable lifestyle factors on 
gout incidence. Thus, the proposed study aims to examine the determinants and disparities of 
gout within an understudied population utilizing data from the Hawaiʻi -Los Angeles Multiethnic 
Cohort (MEC). 
For the proposed study, we hypothesize that (i) an individual’s behavioral lifestyle factors 
(smoking, alcohol use, physical activity, and diet), medical histories (hypertension, other 
cardiovascular conditions, diuretic use, and body mass index), and demographic characteristics 
(ethnicity, sex, age, place of birth, marital status, and education) contribute to the risk of gout, 
and (ii) elevated inflammatory biomarkers and indicators of high purine intake, including CRP, 
γ-tocopherol, and leptin, are positively associated, whereas, carotenoids (α- and β-carotene), α-
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tocopherol, cholesterols, and adiponectin are negatively associated, with gout incidence. The 
objectives of the proposed study are to characterize the disease burden of gout within 
understudied populations and determine modifiable lifestyle factors that may differ between 
populations, especially within an ethnically diverse sample as compared with other well-studied 
populations, and determine the associations between antioxidants, inflammatory biomarkers, and 
gout. 
To address our objective and hypotheses, we plan to accomplish the following specific 
aims utilizing data from the Hawaiʻi-Los Angeles MEC: 1. Ascertain the incidence of gout and 
examine the total effects, direct effects, and risk clustering of modifiable lifestyle factors on 
incident gout among all subjects, Native Hawaiian, Black, White, Japanese, and Latino strata, 
and males and females within the overall and ethnic strata, and 2. Utilizing a sub-sample of 
participants with blood serum data, examine the associations between inflammatory biomarkers 
and antioxidants with gout diagnosis.  
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Section 2. Methods 
2.1 The Multiethnic Cohort Study 
This study utilized secondary data collected from the longstanding Multiethnic Cohort 
Study (MEC) to accomplish the objectives and specific aims. The MEC is a large prospective 
study that has been following a cohort of 215,251 men and women, who were ages 45 to 75 
years old at the time of entry (1993-1997), with approximately 51% from the Los Angeles area 
and 49% from Hawaiʻi. When initiated, the study aimed to explore associations between lifestyle 
factors, primarily dietary components, and cancer within five major racial/ethnic groups with 
distinct cultural and dietary behaviors: non-Hispanic White, Japanese American, Native 
Hawaiian, Black, and Latino. At baseline all participants completed a 26-page self-administered 
questionnaire containing items pertaining to their demographic characteristics, medical histories, 
physical activity, dietary behaviors, and current and past medication/supplement use. The full 
questionnaire was repeated between 2003-2007, and brief follow-up questionnaires were 
repeated for the years 1999-2002 and 2010-2012.  
The primary sampling frame from the original MEC utilized drivers’ license files from 
both Hawaiʻi and Los Angeles to obtain a representative sample from all demographic strata, 
including age and sex. In addition, voters’ registration files were used to identify some names 
that were not included in the Hawaiʻi drivers’ license files, and Health Care Financing 
Administration files were used to identify some of the Black population from Los Angeles. In 
order to prevent oversampling of Whites and focus on the racial/ethnic populations of interest, 
MEC investigators utilized ethnic-specific surnames to estimate the ethno-racial characteristics 
of the sampling frame from data sources without this information. Because surnames did not 
distinguish between those of Black or White descent, census tracts of Los Angeles were used to 
sample from specific areas with a certain proportion of Black residents; in addition, potential 
Black participants were contacted in southern and northern California counties. The final 
classification of race/ethnicity was assigned using the responses to the MEC questionnaire, 
which corrected for any errors during sampling. The 26-page self-administered questionnaire 
was mailed out in waves of approximately 100,000 subjects between 1993 to 1996. Up to three 
attempts were made to mail the questionnaire to each potential subject. The final sample 
ethnic/racial distribution at baseline were as follows: 26.4% Japanese, 22.9% White, 22.0% 
Latino, 16.3% Black, 6.5% Native Hawaiian, and 5.8% Other. 
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2.2 Medicare Linkage and Biospecimen Sub-cohort 
The MEC participants who responded to the initial questionnaire were linked to Centers 
for Medicare & Medicaid Services (CMS) claims data (from 1999-2012) using Social Security 
numbers, sex, and date of birth. Records from 184,299 of the approximately 215,000 participants 
(85%) were sent to CMS for linkage; the remaining 15% of participants’ records were not sent 
due to ineligibility for Medicare at the time of linkage, death prior to reaching 65 years of age, or 
lack of a Social Security number. In total, 170,766 participant records (93% of those sent to 
CMS) were successfully linked to their Medicare data. 
Between 2001 and 2006, a biorepository of blood and urine was created using 
approximately 70,000 of the original MEC participants from both states. Baseline participants 
were initially recruited for the biospecimen sub-cohort by mailed letter describing the requested 
biological requirements. Those who agreed to participate were contacted for a phone interview, 
which included a short screening questionnaire and updates on certain items from the baseline 
questionnaire. Blood and urine samples were collected either at a clinical laboratory or in the 
participants’ home. Eighty-three percent of blood samples were collected after fasting, and 
separated into serum, plasma, buffy coat, and red cells under yellow light. Urine samples were 
collected in the morning from the Los Angeles participants, and collected overnight from 
Hawaiʻi participants. Blood specimens were stored in multiple 0.5 cc aliquots in vapor phase 
liquid nitrogen, and urine samples were stored in five 2 mL aliquots per subject in freezers set to 
-80°C. 
2.3 Study Population and Design 
To address the specific aims in this thesis, two studies were conducted, each employing 
participants from different sub-samples from the MEC: Aim 1 utilized MEC baseline 
questionnaire data linked to Medicare claims data, and Aim 2 compared blood serum data from 
the MEC biorepository to linked data from the baseline questionnaire; from here on, the studies 
addressing Aim 1 and Aim 2 are referred to as Study 1 and Study 2, respectively. Participants for 
Study 1 derived from the 170,766 participants whose records were successfully linked to CMS 
data; analysis was limited to MEC fee-for-service Medicare enrollees, as the outcome was based 
on Medicare claims. The presence or absence of gout claims observed from baseline to the time 
of the most recent CMS linkage (2019) were used to ascertain overall incidence, ethnic and sex 
differences in incidence, and associated modifiable risk factors, of gout among respondents. 
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Study 2 derived data from the MEC biorepository, existing data on CRP, tocopherols, provitamin 
A carotenoids, triglycerides, cholesterols, adiponectin, and leptin from prior blood serum 
analyses was used to examine the relationships with gout cases. Both studies take advantage of 
the prospective, longitudinal design of the MEC, and exclude cases of gout established prior to 
the two baselines (baseline questionnaire for Study 1, and blood draw for Study 2). Based on our 
exclusion criteria, Figure 1 provides the derivation of the final analytic samples the two studies. 
Use of these data have been approved (as exempt status) by the University of Hawaiʻi Office of 
Research Compliance Human Studies Program (Protocol ID: 2018-00912). 
[Figure 1] 
2.4 Ascertainment of Gout Cases 
For both Study 1 and Study 2, we focused on incident gout based on Medicare claims. 
ICD-9 code 274.9 and ICD-10 code M10.9 were used to identify gout diagnosis. Individuals 
reporting gout in the baseline questionnaire were excluded. To exclude prior cases of gout at 
baseline, we used both the lack of Medicare claims data, along with the baseline questionnaire, 
which asks participants “has your doctor ever told you that you had any of the following? (Mark 
all that apply)”. Under this question, one of the responses is “Gout (high uric acid)”. Participants 
who marked this response were excluded from the analyses of Study 1. Additionally, Study 2 not 
only excluded cases prior to the 1993-1997 baseline questionnaire, but also cases of gout prior to 
blood draw, effectively establishing a second start-point (baseline) specific to the Study 2 
subsample. In Study 2, we examined incident gout in order to ascertain the predictive capacity of 
biomolecules outside of the well-established uric acid. 
2.5 Demographics, Behavioral Factors, and other Covariates 
 Data for the demographic characteristics used in both Study 1 and Study 2 were 
ascertained from self-reported responses to the 1993-1997 MEC baseline questionnaire. These 
data include items in which participants report their sex (male or female), marital status (married, 
separated, divorced, widowed, or never married), birth place of participant- mother, and father 
(USA, Mexico, Central or South America, Europe, Africa, Cuba or Caribbean Islands, 
China/Hong Kong/Taiwan, Japan/Okinawa, Korea, Philippines, or Other [write in]), racial/ethnic 
background (Black, Chinese, Filipino, Hawaiian, Japanese, Korean, Mexican/Other Hispanic, 
White, or Other), current weight (in kilograms or pounds), height (in centimeter or feet/inches), 
and years of school completed (did not complete 6th grade, 6th – 8th grade, 9th-10th grade, 11th-12th 
13 
 
grade, vocational school, some college, graduated college, or graduate/professional school). 
Other demographic information was obtained by self-reported responses to the baseline 
questionnaire, including date of birth, Native Hawaiian ancestry, and sex. Generation in the US 
was derived from the self-reported birth places of the participant and the participant’s mother and 
father. First generation participants were individuals born in the US, but one or both parents were 
born in another country; greater than first generation was defined as both parents and the 
participant were born in the US; and, immigrants were born outside of the US.  
Modifiable lifestyle exposures were determined via self-report from the MEC baseline 
questionnaire including: smoking status (including number of years smoking, average number of 
cigarettes per day, and time since cessation), vitamin C supplementation, physical activity 
(including sleep duration, hours per day spend engaging in specific activities, and hours per day 
engaged in various activity levels), and an exhaustive food frequency questionnaire, including 
items pertaining to alcohol use, food group intakes (e.g. specific meats, fruits, vegetables, and 
starches), and beverage intake (e.g. sugar -sweetened beverage, coffee consumption, and tea 
consumption). A summary of energy expenditure (metabolic equivalent tasks [MET]) was 
calculated from responses to items pertaining to physical activity with the formula: ([number of 
hours sleeping × 0.91] + [number of hours sitting × 1.0] + [number of hours in light activity × 
2.4] + [number of hours in moderate activity × 4.0] + [number of hours in vigorous activity])/24. 
Dietary quality was assessed by calculating the Dietary Approaches to Stop Hypertension 
(DASH) diet adherence scores, utilizing methods pioneered by Fung et al.58, from the MEC’s 
food frequency questionnaire. Moreover, medication use and histories of other health conditions 
are also self-reported via the baseline questionnaire, including items on water pill (diuretic) use 
and history of hypertension, diabetes, other cardiovascular diseases/events, and kidney stones. 
2.6 Blood Serum, Inflammatory Biomarkers, and Antioxidants 
 Blood serum assays were performed by the Analytical Biochemistry Shared Resource at 
the University of Hawaiʻi Cancer Center. Laboratory assay procedures have been described 
elsewhere.59,60 In brief, serum concentrations of antioxidants, including carotenoids, tocopherols, 
coenzyme Q10 (CoQ10), and retinol, were ascertained through though high-performance liquid 
chromatography with photo diode array detection and mass spectra. Assays were validated 
through inclusion of external standards, and by participation in quality assurance programs of the 
U.S. National Institute of Standards and Technology.61 Serum C-reactive protein (CRP) levels 
14 
 
were measured using an autoanalyzer, Cobas MiraPlus (Roche Diagnostics, Switzerland) clinical 
chemistry analyzer.  
2.7 Statistical Analyses 
Statistical analyses were conducted at the University of Hawaiʻi at Mānoa with the 
assistance of Lynne Wilkens, DrPH, of the UH Cancer Center, and Yan Yan Wu, PhD, of the 
Office of Public Health Studies. All analyses were conducted using R v3.6.0 with graphic user 
interface RStudio version 1.1.463. 
Aim 1. Ascertain the incidence of gout and examine the total effects, direct effects, and risk 
clustering of modifiable lifestyle factors on incident gout among all subjects, Native Hawaiian, 
Black, White, Japanese, and Latino strata within the overall and ethnic strata. 
To ascertain the incidence of gout, we calculated the incidence density rate (IDR) of gout 
based on Medicare claims and plot the cumulative incidence by age of gout claim, for each 
strata. The cumulative incidence of gout was defined by the number of new gout cases 
throughout the approximately 20-year duration of the study (from cohort entry at baseline to the 
CMS linkage) divided by the number of participants at the beginning of the study period. The 
IDR was defined as the number of new cases in the study sample over the sum of the person-
years per 1,000 of the participants (biostat3::survRate [R package::function]). Using both Chi-
square and t-tests, where appropriate, descriptive statistics summarized the overall baseline 
characteristics, and contrasted the ethnic-strata and sex-strata within ethnicity on these 
characteristics.  
The demographic and modifiable determinants of gout diagnosis were analyzed using a 
racial/ethnic-stratified Cox proportional hazard regression with age, in years, of gout diagnosis as 
the time metric, to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). The time 
metric began at the age of cohort entry (age at 1993-1997 baseline questionnaire), and ends 
either at the age of gout diagnosis or the end of follow-up (CMS linkage in 2019). In addition to 
crude models, ethnicity-stratified Cox proportional hazard models were constructed utilizing an 
evidence-based, theoretical directed acyclic graph (DAG) of known covariates and their 
relationships in relation to gout (Appendix Part I: Figure S1). For the DAG, we reviewed 
abstracts and full-text articles that characterized the directional and/or temporal effects of 
demographic and behavioral factors on gout risk, and among one another. Where no literature 
existed on the topic, we used professional judgement to hypothesize the direction of the 
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relationship between the covariates. The DAG was then analyzed using Dagitty v2.3 for causal 
effect identification, producing minimum sufficient adjustment sets for the total and direct 
effects of each covariate of interest.62  
From the DAG analyses, we constructed three models for each modifiable behavior to be 
applied to each sub-analysis. The first model (Model 1) aimed to examine the total effects of 
each modifiable risk behavior, generally adjusting for demographic characteristic (sex in the 
ethnicity-stratified analyses), education level, and marital status); however, the total effects 
model = of DASH diet additionally adjusted for alcohol use Model 2 aimed to determine the 
theoretical direct effects given the minimum sufficient adjustment sets as defined by the DAG 
analysis. Aside from sex, BMI, education level, generation in the United States, marital status, 
each modifiable behavior had different adjustment sets, summarized in Appendix Part I: Table 
S3. Finally, the third model (Model 3) adjusted for all demographic and all other primary 
exposure/modifiable lifestyle factors considered in the DAG, including sex, education level, 
marital status, generation in the United States, BMI, history of cardiovascular disease, and 
history of kidney stones.  
We examined adherence to the proportional hazards assumption by testing for a non-zero 
slope in a generalized linear regression of a set of scaled Schoenfeld residuals from each 
covariate with time (survival::cox.zph). Each corresponding Schoenfeld residual that was 
significantly (p < 0.05) associated with time was plotted for further visual examination. If the 
covariate was determined to be in severe violation of the proportional hazard assumption, 
transformations were made, including splitting continuous variables into quintiles, and 
aggregating variable levels with little theoretical difference on the outcome and few individuals 
within a level. For categorical confounders, a strata term was added to the regression formula. 
All final models, summarized in Appendix Part I: Table S4, satisfied the proportional hazards 
assumption to a reasonable degree of certainty, with few exceptions (discussed below). 
Risk profiles of gout were elucidated with an exploratory conditional inference survival 
tree analysis, a non-parametric recursive partitioning method that integrates tree-structured 
regression modeling into a conditional inference algorithm.63 Conditional inference (party::ctree) 
survival trees have been used to identify important predictive factor clusters for other chronic 
conditions, including cardiovascular disease and chronic kidney disease incidence.64,65 In short, 
the recursive partitioning algorithm classifies participants into subgroups based on similar 
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reports of an event or outcome variable; the survival tree follows three recurring steps: 1. identify 
a variable with most statistically significant (lowest p-value) ability to differentiate incident gout 
cases from non-cases among a large set of baseline factors from permutation distributions, 2. 
perform a dichotomous split of the data by the identified variable into subsample or nodes, and 3. 
repeat the prior two steps for each subsequent node until the stop criteria is met. For continuous 
explanatory variables, such as BMI, the algorithm will select one cut-point based on the largest 
differences between subjects on the outcome. The stop splitting criterion will include a 5% level 
of significance and a minimum sample size to split a node of 1,000. The terminal node displays a 
Kaplan-Meier curve representing the hazards within the subgroup identified by the survival tree 
algorithm. 
The purpose of the survival tree analysis was to identify important combinations of? 
lifestyle factors that may not have been captured by the Cox regression, with a primary focus on 
dietary behaviors. Thus, in addition to the demographic and behavioral factors included in the 
Cox proportional hazard models, we selected a total of 449 dietary variables, derived directly or 
calculated from the MEC questionnaires’ food frequency questions, relating to intake of specific 
food items, food groups, calculated micronutrients, and diet quality score components that were 
included in the ctree algorithm (Appendix Part I: Table S5). A separate survival tree was 
produced for the overall sample, each ethnic group, and each sex, identifying important 
predictors of gout among each group. 
Aim 2. Utilizing a sub-sample of participants with blood serum data, examine the associations 
between inflammatory biomarkers and antioxidants and gout diagnosis 
Repeating a similar analysis from Aim 1 utilizing the sub-sample from the biorepository, 
descriptive statistics will be used to summarize the overall and racial/ethnic-strata participant 
characteristics, and, using both Chi-square and t-tests; the characteristics will be further 
separated by all participants who were diagnosed with gout versus those who exited the 
observation period without a gout diagnosis (Table 3). To measure the relationships between 
gout histories and biomolecules, we used Cox proportional hazard models, with age as the time 
metric, to estimate HRs and 95% CIs for the overall sample.  
In addition to the crude, Study 2 includes two adjustment models: Model 1 adjusted for 
age, sex, and ethnicity, and Model 2 adjusted for additional demographic and lifestyle factors, 
along with health condition history, from the original baseline questionnaire. Both models 
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included tocopherols (α- and γ-tocopherol, measured in mg/L), carotenoids (α- and β-carotene, 
measured in ng/mL), cholesterols (total, low-density lipoproteins [LDL], and high-density 
lipoproteins [HDL], measured in mg/dL), triglycerides (measured in mg/dL), adipose protein 
hormones (adiponectin, measured in μg/mL, and leptin, measured in mg/L), and known 
inflammatory biomarker CRP (measured continuously in mg/L).  
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Section 3. Results 
3.1 Study 1 – Modifiable Lifestyles and Behaviors 
[Table 1] 
3.1.1 Baseline Characteristics 
Table 1 presents the baseline sample characteristics for the 107,105 MEC participants 
included in Study 1 by ethnic group, and Table 2 reports the baseline sample characteristics for 
male and female strata within each ethnic group: Black (N = 15,660), Native Hawaiian (N = 
7,600), Japanese (N = 32,923), Latino (N = 21,793), and White (N=29,129). Overall, bivariate 
tests for associations found that each ethnic subsample differed significantly on all baseline 
characteristics, including demographics and behavioral factors utilizing Chi-Squared tests for 
association and the Student’s T-test.  
[Table 2] 
3.1.2 Incidence of Gout by Ethnicity and Sex 
Figure 2 presents the cumulative incidence of gout over age at Medicare claim by 
ethnicity, and by sex and ethnicity in Figure 3. The total sample was followed for an average of 
18.12 years (Black = 17.45 years, Hawaiian = 17.78 years, Japanese = 18.23 years, Latino = 
18.44 years, and White = 18.21 years). 11,369 participants (10.87%) of the total were diagnosed 
with gout over the period of observation, as defined by Medicare claim ICD-9-CM 274.9 or 
ICD-10-CM M10.9. The overall incidence rate of gout was 5.997 (95%CI: 5.889, 6.107) per 
1,000 person-years for the total, aggregated sample.  
Across ethnic groups, Native Hawaiians had the highest incidence of gout compared to 
all other ethnic groups, with 17.72% becoming cases throughout the study period, resulting in an 
incidence rate of 9.971 (95%CI: 9.445, 10.518) per 1,000 person-years. Black and Japanese 
subsamples had similar IDRs (7.39 (95%CI: 7.071, 7.719) and 6.39 (95% CI: 6.192, 6.598) per 
1,000 person-years, respectively) with Black participants having slightly more gout cases 
(12.89%) compared to Japanese (11.65%). The lowest incidence of gout was observed among 
White and Latino subsamples, with an IDR of 5.07 (95%CI: 4.885, 5.270) per 1,000 among 
Whites, and an IDR of 4.34 (95%CI: 4.140, 4.550) per 1,000 among Latino participants. 
[Figure 1] 
Within each ethnicity and across the ethnicity-aggregated sample, males had a higher 
incidence of gout (Appendix Part I: Table S2 & Figure S2), with an IDR of 7.41 (95%CI: 7.22, 
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7.60) per 1,000 person-years, overall. The largest IDR (12.90 [95%CI: 11.94, 13.93] per 1,000 
person-years) were observed among Native Hawaiian males (Figure 3). Among the male strata, 
Japanese had the second highest incidence (9.28 [95%CI: 8.91, 9.67] per 1,000 person-years), 
followed by Blacks (7.57 [95%CI: 7.01, 8.17] per 1,000 person-years), Whites (6.27 [95%CI: 
5.95, 6.60] per 1,000 person-years), and Latinos (4.68 [95%CI: 4.38, 5.01] per 1,000 person-
years).  
While females generally had a lower incidence of gout compared to males (5.01 [95%CI: 
4.88, 5.14] per 1,000 person-years), Native Hawaiian women had a greater IDR (8.18 [95%CI: 
7.58, 8.82] per 1,000 person-years) than Black, Latino, and White males (Figure 3, Appendix 
Part I: Table S2). Black women had the second highest incidence among women (7.30 [95%CI: 
6.91, 7.70] per 1,000 person-years), followed by Japanese (4.37 [95%CI: 4.16, 4.60] per 1,000 
person-years), Whites (4.15 [95%CI: 3.93, 4.39] per 1,000 person-years), and Latinos (4.06 
[95%CI: 3.80, 4.33] per 1,000 person-years). 
[Figure 3] 
3.1.3 Ethnicity-Stratified Cox Proportional Hazards Models 
Table 3 summarizes the crude, total and direct through minimum sufficient adjustment, 
and over-adjusted Model 3, effects of modifiable behaviors on gout incidence by each ethnic 
subsample, estimated by multiple Cox proportional hazard regressions. Effects of modifiable 
behaviors for the ethnicity disaggregated sample are also reported. Given the near ubiquitous 
lack of appreciable attenuation of the observed effects between Model 2 and Model 3, we discuss 
the following findings of Model 2 as the direct effects of each behavioral risk factor, along with 
the total effects observed in Model 1.  
[Table 3] 
Diet Quality 
  Higher tertiles of the total DASH scores were significantly associated with a decreased 
risk of gout incidence across most ethnic subsamples in all models compared to the lowest tertile, 
apart from Latinos (tertile 2 HR: 0.91, 95%CI: 0.80, 1.04; tertile 3 HR: 0.90, 95%CI: 0.78, 1.03). 
The direct effect of DASH score was largest among White and Japanese participants in both 
tertile 2 (HR: 0.81, 95%CI: 0.75, 0.88 among Japanese, and HR: 0.79, 95%CI: 0.71, 0.87 among 
Whites) and tertile 3 (HR: 0.77, 95%CI: 0.70, 0.84 among Japanese, and HR: 0.70, 95%CI: 0.63, 
0.78 among Whites). Black and Native Hawaiian participants risk of gout was similarly 
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decreased by tertiles of DASH scores; DASH tertile 2 was associated with a 15% (95%CI: 2-
30%) and 16% (95%CI: 2-33%) decreased risk, and DASH tertile 3 was associated with a 22% 
(95%CI: 8-39%) and 23% (95%CI: 6-45%) decreased risk, among Black and Native Hawaiian 
groups, respectively. 
Alcohol Consumption 
Across most ethnic groups, increasing alcohol consumption was associated with an 
increased risk of incident gout, with the largest effects observed among Japanese and Black 
participants, with little attenuation between models 1-3. Among Japanese drinkers, the direct 
effects of one to two alcoholic drinks per day was associated with a 21% (HR: 1.21, 95%CI: 
1.09, 1.34) increased risk of gout, and three or more alcoholic drinks per day was associated with 
a 47% (HR: 1.47, 95% CI: 1.28, 1.69) increased risk, compared to those reporting no alcohol use 
per day. Similar effects in both higher (HR: 1.55, 95%CI: 1.23,1.94) and lower levels (HR: 1.20, 
95%CI: 1.03, 1.40) of alcohol use were observed among Black participants. The direct effect of 
alcohol use was similar among Native Hawaiian and White subjects, with no significant effect 
detected in the lower (one to two alcoholic drinks per day) level, but a 34% (95%CI: 9-64%) and 
33% (95%CI: 18-51%) increased risk of gout, within the three or more alcoholic drinks groups 
compared to no alcohol use, for Native Hawaiians and Whites, respectively. Alcohol use was not 
significantly associated with risk of gout among Latinos for both one to two (HR: 1.09, 95%CI: 
0.93, 1.27) and three or more (HR: 1.16, 95%CI: 0.93, 1.45) alcoholic drink levels compared to 
no alcohol use.  
Smoking, Vitamin C Supplementation, and Physical Activity 
 The observed total and direct effects of smoking, vitamin C supplementation, and 
physical activity on incident gout risk differed by ethnic subsample compared to DASH and 
alcohol use. After adjusting for sex, education level, generation in the US, and marital status 
(total effect, Model 1), current smoking was only significantly associated with an increased risk 
of gout among Black (HR: 1.33, 95%CI: 1.18, 1.52) and Japanese (HR: 1.27, 95%CI: 1.14, 1.42) 
subsample, compared to never smokers; these effect attenuated but persisted in statistical 
significance in the direct effects model 2, with current smoking associated with a 31% (95%CI: 
13-52%) and 18% (95%CI: 4-33%) increased risk among Blacks and Japanese, respectively. 
While the total effects of past smoking was significantly associated with an increased risk of 
gout among Black (HR: 1.13 [1.01, 1.25]), Japanese (HR: 1.14 [1.06, 1.23]), Latino (HR: 1.12 
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[1.01, 1.26]), and White (HR: 1.14 [1.04, 1.24]) groups, past smoking was not significant in the 
direct effects model among any of the ethnic groups. 
 The total effects of vitamin C supplementation was associated with a significant 
decreased risk of gout incidence among Native Hawaiians (HR: 0.81, 95%CI: 0.71, 0.92), 
Japanese (HR: 0.86, 95%CI: 0.80, 0.92), and Latinos (HR: 0.88, 95%CI: 0.79, 0.98). In the direct 
effects model, vitamin C supplementation was associated with a 15% (95%CI: 0.3-32%) 
decreased risk of incident gout among Native Hawaiians, and a 10% (95%CI: 2-18%) among 
Japanese. Among Latinos, vitamin C supplementation was not significantly associated with 
incident gout in the direct effects model (HR: 0.99, 95%CI: 0.88, 1.11). 
 Finally, the total effects of physical activity, measured by metabolic equivalent score, 
was associated with a 42% (95%CI: 19-69%) decreased risk of gout among Latino, and a slight 
decreased risk among Black participants (HR: 0.82, 95%CI: 0.68, 0.99). Physical activity was 
only significantly associated with a decreased gout incidence in the direct effects model among 
Latinos (HR: 0.77, 95%CI: 0.64, 0.93). 
Model Diagnostics 
The proportional hazards assumption was tested for each model within the ethnic strata; 
final covariate transformations and assumption results from these tests are available in the 
Appendix Part II: Page 84-101. In brief, diagnostic tests for models used to assess the direct 
effects of alcohol use showed that that the results presented for Native Hawaiian, Japanese, 
Latino, and White subsamples met the cox proportional hazards assumption; the Black 
subsamples slightly failed on one of the two levels of alcoholic drinks per day, showing a very 
slight negative slope with time for the one to two drinks per day level among Blacks in the direct 
effects model (rho = -0.05203, p = 0.0448). Similarly, smoking status met the assumption in all 
ethnic sub-analyses, apart from the Black regression, in which current smoking residuals were 
slightly associated with the time metric (rho = -0.05293, p = 0.0411). Nearly all DASH score 
models failed to meet the proportional hazards assumption, except for Latino subsamples; 
however, these violations were limited to the third tertile residual comparison, while the second 
tertile met the assumption in all models.  
Overall, visual inspection of corresponding weighted Schoenfeld residual plots 
(Appendix Part II) further revealed little non-proportionality across levels of the primary 
covariates. Among models that found a statistically significant violation of the proportional 
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hazard assumption, residual plots against time qualitatively suggested a negligible association, 
specifically regarding smoking status and alcohol use. However, Schoenfeld residual plots of the 
third tertile DASH score suggested a notable deviation from the proportional hazard assumption.  
3.1.4 Risk Clusters Identified Through Recursive Partitioning 
[Figure 4] 
The conditional inference survival tree analysis for the total, ethnic-disaggregated sample 
is presented in Figure 4, and survival trees for each ethnicity are presented in Figure 5a-e. For 
each survival tree, the terminal node produced a survival curve (proportion of individuals 
without a gout claim by time (age in years)) for those within the preceding risk profile above. 
In the total sample, the ctree algorithm first split the root node by BMI with the cut-point 
25.843 kg/m2 (p < 0.001). On the left-most side (Appendix Part I: Figure S3a) of the total 
survival tree, less than or equal to BMI 25.843 kg/m2, subgroups were split by density of 
potassium intake (cut-point: 1,305.794 mg/kcal/day; p < 0.001). For those that consumed less 
potassium (≤1,305.794 mg/kcal/day), nodes were then split by BMI cut-point 22.545 kg/m2, with 
lower BMI further split by calculated density of nitrosamine intake (cut-point: 0.097 
mcg/kcal/day; p < 0.001), and higher BMI split by alternative Healthy Eating Index-2010 
component: Omega-3 Fatty Acid intake (cut-point: 7.422; p < 0.001). Among those of who 
consumed more potassium (> 1,305.794 mg/kcal/day), subgroups were split by >1st generation in 
the US and immigrants to the US versus 1st generation; >1st generation and immigrants were split 
by Ethnicity (Black, Latino, and White vs. Native Hawaiian and Japanese; p < 0.001), and 1st 
generation citizens were split by BMI (cut-point: 22.921 kg/m2; p < 0.001).  
On the right side of the first split (Appendix Part I: Figure S3b), greater than BMI 25.843 
kg/m2, the subgroup was split by Ethnicity (Black, Japanese, Latino, and White versus Native 
Hawaiian; p < 0.001). Within the Black, Japanese, Latino, and White node 18, Ethnicity was 
split again (p < 0.001) into a node of Black, Japanese, and White, which were subsequently split 
by sex (p < 0.001), and a Latino node, which was split by White Rice intake (cut-point: 285.526 
g/day; p < 0.001). The Native Hawaiian subgroup (node 17 split) was subsequently split by 
History of Hypertension (p < 0.001); those (Native Hawaiian with BMI > 25.843 kg/m2) without 
a History of Hypertension were then split by sex (p < 0.001), while those with a History of 
Hypertension were split by White Rice intake (cut-point: 285.526 g/day; p < 0.001). Overall, 
covariates on the right-most side of the tree corresponded with the most important factors and 
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levels in risk of incident gout; that is, the survival tree identified Native Hawaiians with a BMI of 
> 25.843, a history of hypertension, and high consumption of white rice (> 285.526 g/day) had 
the highest risk of gout, as shown in the terminal node 31.  
[Figure 5a-e] 
Within the ethnic-specific conditional inference analyses (Figures 5a-e), BMI was 
identified across all ethnicities, being the first splitting variable among all, except the Japanese, 
subsamples, indicating its relative importance over other covariates. First-level BMI cut-points 
differed slightly between most ethnic groups, with the lowest among Whites (BMI = 26.737 
kg/m2; p < 0.001); however, after splitting by sex (p < 0.001), BMI among Japanese males split 
at 25.97 kg/m2 (p < 0.001), and females at 23.964 kg/m2 (p < 0.001). Similarly, History of 
Hypertension was also consistently identified as a subsequent (second tier) splitting variable 
among nearly all ethnic groups, again apart from Japanese, in which History of Hypertension 
was not selected in any node. The algorithm also selected white rice consumption among Native 
Hawaiians, Latinos, and Whites, showing a steeper survival curve within higher levels of 
consumption.  
Despite its suggested importance in the overall sample, Potassium intake (cut-point: 
1,608.923 mg/kcal/day; p < 0.001) was only identified within the Black subsample. Other unique 
factors identified within specific ethnic groups included: percent of calories from dairy fats (cut-
point: 1.877%; p = 0.003) and Poultry/Fish intake (cut-point: 9.128 cups/day; p = 0.005) among 
Blacks (Figure 5a); Spam/Bologna/Pastrami intake (cut-point: 5.14 g/day; p = 0.006) and Dietary 
Fiber intake density (cut-point: 7.49 g/kcal/day; p < 0.001) among Native Hawaiians (Figure 5b); 
Generation in the US (>1st generation and immigrant versus 1st generation Americans; p < 
0.001), Fruit component of the energy-adjusted Mediterranean Diet score (cut-point: 0, p = 
0.034), diuretic use (Never versus Past and Current; p < 0.001), total DASH score (cut-point: 21; 
p < 0.001), and copper intake density (cut-point: 0.63 mg/kcal/day; p = 0.004) among Japanese 
(Figure 5c). The White subsample ctree (Figure 5e) identified the most unique variables relative 
to the other ethnicities, including: Omega-3 Fatty Acid component of the adjusted Healthy 
Eating Index 2010 (cut-point: 5.782; p < 0.001), dairy product intake density (cut-point: 161.477 
g/kcal/day; p < 0.001), salted and dried fish intake (cut-point: 0 g/day; p < 0.001), number of 
alcoholic drinks per day (0 and 1-2 drinks versus three or more drinks; p = 0.02), riboflavin 
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intake density (cut-points: 0.803 and 0.820 mg/kcal/day; p = 0.012 and p = 0.044, respectively), 
and meat intake (cut-point: 1.148 oz/day; p < 0.001).  
3.2 Study 2 – Biomarkers and Antioxidants 
[Table 4] 
3.2.1 Baseline Characteristics and Biomolecule Summary 
 A summary of the univariate baseline characteristics of Study 2 participants is available 
in the Appendix Part I: Table S7. At baseline, the Study 2 subsample was disproportionately 
Latino (32.68%), Female (54.59%), born in the US (80.27%), married (70.68%), overweight 
(41.17%), never smokers (47.94%), non-daily drinkers (76.35%), non-vitamin C users (61.33%), 
and with no history of diuretic use (80.98%); additionally, at baseline, Study 2 participants had a 
mean METs score of 1.63±0.31 and a mean DASH score of 24.05±4.34. Blood draws took place 
between 1994 and 2006 (the majority between 2002-2004), with a mean age at blood draw of 
67.63±7.72 years.  
Baseline sample characteristics by incident gout for the 6,567 MEC participants with 
blood draw data are shown in Table 4. Table 5 presents the bivariate summary of the serum 
concentrations (analyzed continuously and categorized into tertiles) of C-reactive protein, 
cholesterols, triglycerides, tocopherols, carotenes, adiponectin, and leptin at blood draw by gout 
incidence.  
[Table 5] 
3.2.2 Cox Proportional Hazards Models 
 Table 6 presents the crude, sex- & ethnicity-adjusted (Model 1), and baseline 
characteristic-adjusted (Model 2) hazard ratios for tertiles of biomolecule serum concentrations, 
as estimated by multiple Cox proportional hazards regressions. Each model met the proportional 
hazards assumption (Appendix Part II: Page 103-107) after making the appropriate 
transformations, with the exception of Model 1 α- and γ-tocopherol; all corresponding final 
formulae are presented in Appendix Part II: Page 103-107.  
[Table 6] 
 Compared to the lowest tertile, the highest tertile of serum CRP (HR: 1.84, 95%CI: 1.51, 
2.25), triglycerides (HR: 1.83, 95%CI: 1.50, 2.23), γ-tocopherol (HR: 1.69, 95%CI: 1.35, 2.11), 
and leptin (HR: 2.73, 95%CI: 2.14, 3.47) was significantly increased among incident gout cases, 
after adjusting for age of diagnosis, sex, and ethnicity. The middle tertile for triglycerides (HR: 
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1.34, 95%CI: 1.10, 1.65) and leptin (HR: 1.55, 95%CI: 1.26, 1.91) were also associated with a 
significantly higher risk of incident gout, compared to the lowest tertile; while tertile 2 CRP (HR: 
1.21, 95%CI: 0.98, 1.49) and γ-tocopherol (HR: 1.17, 95%CI: 0.93, 1.47) concentrations 
followed the same (risk-elevating) directionality as tertile 3 comparisons, these associations were 
not statistically significant in the adjusted models. None of the risk-increasing associations 
attenuated to statistical insignificance after additionally adjusting for education level, place of 
birth, BMI, marital status, smoking status, vitamin C supplementation, physical activity, alcohol 
consumption, diuretic use, and dietary quality.  
  Compared to tertile 1, Model 1 adiponectin concentrations were associated with a 
decreased risk of gout in both tertile 2 (HR: 0.76, 95%CI: 0.63, 0.92) and tertile 3 (HR: 0.67, 
95%CI: 0.54, 0.82). Similarly, the highest tertile concentration of both α- and β-carotene were 
both associated with a decreased risk of gout by 79% (95%CI: 43-127%), and 92% (95%CI: 52-
144%), respectively, versus the lowest tertile. Moreover, the middle tertile of both α-carotene 
(HR: 0.68, 95%CI: 0.55, 0.84) and β-carotene (HR: 0.62, 95%CI: 0.50, 0.76) significantly 
reduced gout risk in Model 1. HDL-cholesterol was associated with a 61% (95%CI: 30-96%) 
decreased risk of incident gout for the highest versus the lowest tertile serum concentrations, 
after adjusting for age, sex, and ethnicity; however, the middle tertile was not. After adjusting for 
other baseline characteristics (Model 2), the inverse associations attenuated, but remained 
statistically significant. Finally, despite their crude associations, serum concentrations of total 
cholesterol (tertile 1 vs. 2 HR: 0.85, 95%CI: 0.70, 1.02; tertile 1 vs. 3 HR: 0.84, 95%CI: 0.69, 
1.03) and α-tocopherol (tertile 1 vs. 2 HR: 0.93, 95%CI: 0.75, 1.15; tertile 1 vs 3 HR: 0.84, 
95%CI: 0.67, 1.05) were not significantly associated with risk of subsequent gout after the first 
adjustment set. 
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Section 4. Discussion 
4.1 Key Findings 
Our study aimed to establish the crude incidence of gout, the risk effect of modifiable 
behaviors, and associations between objectively measured biomolecules and subsequent gout 
within a large, multiethnic longitudinal cohort of older adults. We observed substantial evidence 
of ethnic disparities with regards to gout incidence, as measured by both overall accumulation 
and rate of Medicare claims over an approximately 20-year observation period. Overall, Native 
Hawaiians had the highest rates of gout, with over two times the rate of the lowest incidence 
ethnic group (Latinos). Focusing on sex differences, Native Hawaiian men had the highest 
incidence of gout across the total sample; additionally, Native Hawaiian women had a greater 
incidence than men of nearly all other ethnic groups. The second greatest incidence was 
observed among the Black subsamples, followed successively by Japanese, White, and Latino. 
Men consistently maintained a higher gout incidence than women over the study period; 
Japanese men, whom had the second highest rate overall, had the greatest sex difference within 
an ethnic group, with new cases of gout more than doubling those of Japanese women. Finally, 
we observed that Latinos had the lowest incidence of gout relative to the other ethnic groups in 
our sample. 
Examination of modifiable lifestyle behaviors on incident gout using ethnic-specific Cox 
proportional hazard models provided evidence of both general and differential effects between 
subsamples, indicating that the effects of some behaviors may be modified by ethnicity, while 
others may be more universally related to gout risk. These analyses revealed that only high levels 
of alcohol use significantly elevated risk of incident gout among Native Hawaiians and Whites, 
possibly indicating that moderate use does not contribute to one’s risk of gout within these 
groups; however, consuming one to two alcoholic drinks per day led to an elevation of gout risk 
among the Black and Japanese participants. Similarly, current smoking independently 
contributed to gout risk among Black and Japanese groups in the direct effects models, while no 
such association was observed among Native Hawaiians and Whites. We also observed a slight 
protective association between Vitamin C supplementation and incident gout among Native 
Hawaiians and Japanese, but not within other ethnic groups. Lack of adherence to the DASH diet 
and consumption of three or more alcoholic drinks per day were the most ubiquitous predictors 
of gout across most ethnic groups, whereas smoking, physical activity, and vitamin C appeared 
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to predict incident gout differently according to race/ethnicity. Almost none of the behavioral 
factors in our model had a direct effect on disease incidence among Latinos, with the notable 
exception of a strong inverse relationship between MET score and gout. Interestingly, MET 
score was not associated with gout within any other ethnic group, indicating that its protective 
effects may be specific to those of Latino decent. 
In our exploratory survival tree analysis, we both further confirmed the importance of 
several behavioral and demographic factors identified through the Cox regressions, as well as 
specific dietary factors across and within ethnic strata that may not have been encapsulated by 
the DASH score tertiles. More specifically, we observed gout risk clustering of 1.) demographic 
characteristics, including: sex, ethnicity, and generation in the United States, 2.) medical 
conditions, including: body mass index, history of hypertension, and diuretic usage, and 3.) 
specific dietary components, including: white rice consumption, potassium intake, omega-3 fatty 
acids, alcohol use, riboflavin intake, and consumption of various meat products.   
Lastly, utilizing a subsample of participants with blood serum measurements, we 
determined the tertile effects of objectively measured biomolecules, including antioxidants, 
hormones, and C-reactive protein, on incident gout claims. We found that elevated serum 
concentrations of C-reactive protein, triglycerides, γ-tocopherol, and leptin were significantly 
associated with an increased risk of subsequent gout, all appearing to follow a ‘dose-dependent’ 
pattern. Conversely, HDL-cholesterol, α- and β-carotene, and adiponectin were inversely related 
to gout risk, even after adjustment for baseline confounders. 
4.2 Convergence with Existing Literature 
While our study is the first to examine gout incidence among Native Hawaiians, our 
findings are consistent with the long-standing literature of epidemiological studies on the 
incidence and prevalence of gout within other indigenous Pacific Islander groups, primarily 
conducted on New Zealand Māori.15 A recent systematic review of the distribution of arthritic 
condition within indigenous populations found consistently an approximately three times higher 
proportion of gout cases among the Māori, relative to their White counterparts.66 Nonetheless, 
information on gout within these communities is scarce; in 1978, Brauer & Prior67 published the 
only investigation into the incidence of gout among Pacific Island populations, observing an 11-
year cumulative incidence of 10.3% among Māori men and 4.3% among women. Our 20-year 
cumulative incidence estimates among Native Hawaiians are over twice as high as those 
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observed in Māori men and women; while this may indicate a greater risk, our estimated 
cumulative incidence does not account for differences in age distribution. Nonetheless, 
prevalence estimates show that Native Hawaiians may be disproportionately affected by arthritic 
conditions compared to Asians and White; our findings suggest that much of this disparity may 
be attributed to gout.68 
Prior literature on the disparity between Black and White populations in gout incidence 
are consistent with our findings. As mentioned, investigation of racial differences within the 
ARIC Study in 201450 found that Black participants had a disproportionately higher gender-
specific incidence of gout compared to Whites. Additionally, these researchers found that the 
cumulative incidence of Black women was higher than White men after individuals reached 
approximately 75 years of age.50 While we observed a similar trend comparing gender-specific 
incidence between Black and White subjects, the cumulative incidence of gout among Black 
women did not exceed that of White men until much older ages than reported in previous studies 
(Appendix Part I: Figure S4a).  
Another consistent finding with prior literature is the notably low incidence of gout 
among Latino participants relative to other ethnicities in our sample. While no previous 
investigators have examined incident gout within Latino-American populations, the known 
prevalence estimates from Mexico69, Cuba70, and Guatemala71 are very low compared to other 
regions of the world, suggesting that these groups may not be as affected by the disease. 
While recent trends have suggested that gout may be on the rise within Japanese national 
populations, our findings of relatively high incidence among Japanese participants are generally 
inconsistent with the markedly low prevalence reported from within Japan.72 This is especially 
true when examining sex differences, in which Japanese males from the MEC were among the 
highest in incident gout claims across all other sex and ethnic strata. This inconsistency with 
existing literature may largely be attributed to the acculturation of Western lifestyles in 
Hawaiʻi55, possibly indicating a predisposition to gout when deviating from traditional Japanese 
lifestyles. In addition, some of this inconsistency may be due to the fundamentally different 
ethnic background of Japanese in Hawaiʻi, where we derived the majority of our Japanese 
subjects, compared to Japanese from Japan; that is, a large proportion of the Hawaiʻi-born 
‘Japanese American’ population are Okinawan.73 While the exact proportion of Okinawan to 
mainland Japanese is unknown within both Hawaiʻi and our sample, Okinawans are not only 
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culturally, but genetically distinct, showing notable signs of long-term island-based isolation, 
compared to mainland Japanese individuals.74,75 Our findings may suggest that Okinawans in 
Hawaiʻi have a much higher rate of gout than mainland Japanese, possibility mirroring the high 
rates observed in geographically and genetically similar Taiwan aboriginals (i.e. Ryukyuan 
descendants).75,76 
Across ethnic groups, behavioral risk factor analyses though Cox regression models 
revealed similar relationships from prior literature utilizing other, less diverse, populations. 
While slight modification of the effects by ethnic group was observed, the overall direction of 
the point estimates did not differ from our evidence-based expectations, outlined in our 
hypotheses; specifically, our results further confirmed the previous findings of gout risk, or uric 
acid, elevation from alcohol use and smoking77, and protective effects from vitamin C 
supplementation41,78, physical activity79, and DASH diet.80,81 However, there is a notable lack of 
consensus with regards to smoking status and gout. In a recent meta-analysis utilizing five 
studies examining the effects of smoking status on gout risk, researchers found conflicting 
effects from several large studies, suggested that smoking may not be directly involved in the 
risk of gout, but rather attributable to confounding.82 One possible explanation for our results 
may be that the risk-elevating associations are specific to Black and Japanese/Okinawan groups, 
neither of which were included in the aforementioned meta-analysis; however, further research is 
needed to confirm or reject this proposition. In addition, findings from our survival tree analysis 
identified similar demographic and lifestyle factors described in prior literature and within our 
Cox regression models, including BMI, hypertension, sex, and ethnicity, while many of the 
specific dietary factors were novel, including white rice, potassium, nitrosamines, and copper 
intake. These findings warrant further investigation to ascertain their direct effects on gout and 
elucidate any plausible mechanisms that might explain or disprove their importance. 
Finally, the results from Study 2 were largely consistent with prior biomolecular 
associations with gout and hyperuricemia. For example, a recent study found higher levels of 
leptin, the biomolecule with the strongest effect in our study, among patients with acute gout, 
which in turn promoted MSU-induced inflammation.83 Similarly, CRP, a commonly used 
inflammatory biomarker, has been previously shown to have a direct association with 
hyperuricemia;84 to our knowledge, our study is the first to show this relationship in the disease 
state. Elevations in γ-tocopherol are also thought to be related to a possible response to chronic 
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inflammation, as demonstrated in both in vivo and in vitro studies of cancer85-87, cardiovascular 
disease88, and other age-related morbidities89-92. While not previously investigated with regards 
to acute gout, inverse association between serum uric acid levels and β-carotene93, adiponectin94, 
and HDL-cholesterol95 have been observed in prior literature.  
4.3 Implications in Public Health 
Our studies provide substantial implications for the field of public health by providing 
crucial information on ethnic disparities, behavioral risk factors, and possible biomarker efficacy 
in gout. First, benefitting from Hawaiʻi’s large population of Native Hawaiians and Japanese 
Americans, along with the diverse populations of Latinos and Blacks from the Los Angeles area, 
our findings provide crucial evidence that may inform precision in both the screening and 
intervention of gout. Considering the substantial differences in incidence by ethnicity, healthcare 
professionals and public health programs may utilize our findings to help identifying those at 
high risk of gout. While sex differences were observed, as expected, the decreasing magnitude of 
this difference in the crude incidence among many ethnic strata may help to dispel the myth that 
gout is a male-specific condition, especially when approaching older adulthood. The finding that 
Native Hawaiian women have higher incidence rates compared to males of other ethnic groups is 
crucial in this regard, showing that ethnic disparities in gout may outweigh the well-known sex 
differences. 
This study contributes ethnic-specific total and direct effect estimates to highlight areas 
where individuals within these groups can best benefit from lifestyle modification to mitigate the 
risk of gout. For example, our findings further support that adherence to the DASH diet, 
regardless of ethnic background, may not only decrease risk of hypertension, but also may 
independently reduce gout incidence. Conversely, protective direct effects from physical activity 
was only observed among Latinos, suggesting that physical activity may not be as important in 
reducing gout among other groups. Thus, observing these differences can help target direct or 
underlying behaviors where more general inventions fail. Moreover, addressing the disparities of 
gout among underserved populations can help decrease other subsequent co-morbidities 
associated with gout within populations that already have an increased risk. As a disease strongly 
linked to other co-occurring chronic conditions, preventing gout among older populations that 
are financially disadvantaged may help alleviate future health expenditures in older age. 
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Lastly, establishing biomolecule associations can provide evidence for objectively 
measuring early indication of gout risk, without reliance on self-reported risk factors. While uric 
acid measurements are standard in confirmatory screening and diagnosis, understanding the 
relationships between biomolecules tested in other health-related situations, such as leptin, CRP, 
and γ-tocopherol may provide health providers with early warning signs of gout. Detecting and 
treating disordered levels of these biomolecules in patients with elevated risk profiles may help 
prevent the onset of acute gout. 
4.4 Strengths and Limitations 
There are many strengths to our two studies. First, to our knowledge, this is the first study 
to investigate gout with regards to the incidence, risk factors, and predictive potential of 
biomolecules utilizing large samples of Native Hawaiians, Japanese Americans, Latinos, Blacks, 
and Whites. Through ethnically stratified analyses of the over 100,000 MEC participant, we 
provide important insights into understudied, and often underserved, ethnic minority groups and 
their risk of gout. Secondly, compared to the few prior longitudinal studies on gout, this study 
benefits from a relatively long follow-up period and a small number of lost individuals to follow-
up as a result of linkage with the Medicare claims database; that is, Medicare linkage eliminated 
the need to physically recontact participants after baseline in order to ascertain the outcome. 
Thirdly, we are the first to provide evidence on gout risk factors derived from both traditional 
time-to-event model-based methods, as well as an innovative, data-driven machine learning 
algorithm. A major advantage of survival tree analysis is the ease of interpretation by 
practitioners that may not be accustomed to complex statistical modeling. Furthermore, it has 
been reported that the conditional inference framework provides a more parsimonious clustering 
of participants into subgroups based on time-to-event risk than Cox models. Finally, biomarkers 
are objective measures of health, and drawing connections between specific health conditions 
may glean important implications for, not only mechanistic functions, but screening capabilities 
of these molecules. As mentioned, the objectivity of these measures provides an advantage over 
self-reported measures by avoiding information bias and providing possible insights into 
metabolic/immunologic pathways of gout. 
Despite the many advantages in our approach, these studies are not without limitations. 
First, all baseline items are derived from self-reported responses to questionnaires, which may 
have led to misclassification, particularly with regards to adverse behaviors, such as smoking and 
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alcohol use due to social desirability bias. This would likely have resulted in a nondifferential 
underreporting across the samples, biasing towards the null; that is, there is no substantial reason 
to suspect that individuals that developed gout would differentially misreport behaviors at a 
higher or lower rate than those who did not. Second, while using Medicare claims data likely 
lessened the expected loss to follow-up, it was not possible to ascertain the number of 
participants lost due to the lack of re-contacting. As a result, participants belonging to groups 
that frequently migrate out of the US healthcare system may have been disproportionality lost 
over the observation period, namely Latinos. Moreover, access to care may be different 
depending on socio-economic status and other environmental factors, which may have 
contributed to delays in time-to-event analyses. However, given the age of our sample, Medicare 
coverage is likely available to all participants. Another issue with regards to the use of Medicare 
claims data is that a Medicare claim of gout is not the same as a definitive diagnosis of gout; 
while this may have affected our ability to accurately define the temporal relationship between 
exposure and outcome, the long follow-up period likely mitigated the effects of this limitation.  
Thirdly, some of our Cox models failed the proportional hazards assumption, potentially biasing 
our results towards the alternative hypothesis; namely, DASH adherence scores failed in nearly 
all models. In order to account for this limitation, we conducted the survival tree analysis to 
examine specific dietary components associated with incident gout. Another factor that may have 
led to misclassification of the outcome is misdiagnosis among females; clinical gout has been 
shown to mimic the symptoms of rheumatoid arthritis, which is more common in women than 
men, which may have resulted in a misclassification of the outcome.96,97 Lastly, examining gout 
in adults aged 50-100 years of age limits the generalizability of our findings to older adults, 
missing cases that occur earlier in life. 
4.5 Conclusion and Future Directions 
Overall, we found significant ethnic differences in both the incidence and effects of 
modifiable risk factors in gout. In addition, we found several biomolecular associations 
consistent with prior literature, which may serve as biomarkers of gout. To address some of the 
limitations in methodology and scope, there are several ways future investigations can expand on 
this work. First, researchers could examine the modifying effects of sex within ethnic strata to 
possibly uncover differential effects of behavioral risk factors. Second, gout is a self-limited 
disease, and identifying predictors of recurring gouty attacks may further elucidate the long-term 
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effects of poorly treated gout. Thus, while our study focuses only on gout claims, future studies 
should investigate the time-varying nature of gout and determine which groups are at risk for 
readmission. Finally, updating the direct and indirect costs of gout within underserved groups, 
such as Native Hawaiians, may provide crucial funding information to areas with limited 
financial resources.  
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Figures 
Figure 1. Flowchart of the Final Analytic Samples Derivation 
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Figure 2. Cumulative Incidence of Gout by Ethnicity 
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Figure 3. Cumulative Incidence of Gout by Sex and Ethnicity 
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Figure 4. Risk Clusters of Gout Incidence for the Total Sample Controlling for Age at Diagnosis 
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Figure 5a. Risk Clusters among Black participants for Incident Gout 
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Figure 5b. Risk Clusters for the Native Hawaiian Subsample 
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Figure 5c. Risk Clusters for the Japanese Subsample 
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Figure 5d. Risk Clusters for the Latino Subsample 
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Figure 5e. Risk Clusters for the White Subsample 
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Tables 
Table 1. Baseline Characteristics of the Multiethnic Cohort by Ethnicity, 1993-1997 (N=107,105) 
 Levels/Statistic Black Hawaiian Japanese Latino White p-value 
Sex Male 5,290 (33.78%) 2,969(39.07%) 14,150(42.98%) 10,082(46.26%) 12,929(44.39%) <.0001 Female 10,370 (66.22%) 4,631(60.93%) 18,773(57.02%) 11,711(53.74%) 16,200(55.61%) 
 
Baseline Age mean(SD) 60.50 (8.93) 56.35(8.04) 60.15(8.75) 58.77(7.31) 58.54(8.74) <.0001 
Education 
High School or Less 6,340 (41.15%) 3,931(52.22%) 11,752(35.97%) 14,663(68.65%) 7,097(24.55%) <.0001 
Vocational/Some college 5,479 (35.56%) 2,243(29.80%) 9,781(29.94%) 4,372(20.47%) 9,113(31.53%) 
 
Grad College/Grad School 3,588 (23.29%) 1,354(17.99%) 11,135(34.09%) 2,324(10.88%) 12,693(43.92%) 
 
Generation US 
>1st gen 14,509 (94.82%) 6,597(87.66%) 11,414(34.80%) 3,112(14.35%) 20,912(72.50%) <.0001 
1st gen 262 (1.71%) 902(11.99%) 18,468(56.31%) 6,642(30.62%) 4,760(16.50%) 
 
immigrant 530 (3.46%) 27(0.36%) 2,917(8.89%) 11,939(55.04%) 3,173(11.00%) 
 
Marital Status 
Married 6,598 (42.86%) 5,224(69.10%) 25,543(77.89%) 14,028(65.11%) 19,537(67.53%) <.0001 
Separated/Divorced 4,942 (32.10%) 1,164(15.40%) 2,568(7.83%) 4,021(18.66%) 5,234(18.09%) 
 
Widowed 2,788 (18.11%) 767(10.15%) 2,511(7.66%) 1,979(9.18%) 2,257(7.80%) 
 
Never 1,067 (6.93%) 405(5.36%) 2,173(6.63%) 1,518(7.05%) 1,901(6.57%) 
 
Body Mass Index 
<25 kg/m2 3,958 (26.34%) 2,093(27.93%) 20,119(61.47%) 6,150(28.48%) 13,751(47.43%) <.0001 
25-30 kg/m2 6,219 (41.39%) 2,872(38.33%) 10,426(31.86%) 10,088(46.71%) 10,520(36.28%) 
 
>30 kg/m2 4,849 (32.27%) 2,528(33.74%) 2,183(6.67%) 5,358(24.81%) 4,723(16.29%) 
 
Smoking Status 
Never 6,018 (39.06%) 2,993(39.81%) 17,208(52.73%) 10,403(49.54%) 11,535(39.93%) <.0001 
Past 5,988 (38.87%) 2,823(37.54%) 11,760(36.04%) 7,639(36.38%) 12,792(44.28%) 
 
Current 3,400 (22.07%) 1,703(22.65%) 3,664(11.23%) 2,958(14.09%) 4,562(15.79%) 
 
Vitamin C Supplementation No 8,543 (58.83%) 5,040(69.19%) 18,778(58.61%) 12,934(64.42%) 15,761(55.83%) <.0001 Yes 5,978 (41.17%) 2,244(30.81%) 13,260(41.39%) 7,143(35.58%) 12,469(44.17%) 
 
METs mean(SD) 1.59 (0.29) 1.65(0.35) 1.61(0.27) 1.68(0.32) 1.63(0.30) <.0001 
# of Alcoholic Drinks/Day 
None 12,208 (81.82%) 5,573(76.46%) 26,308(82.82%) 16,515(78.94%) 17,195(61.35%) <.0001 
1 to 2 1,986 (13.31%) 1,151(15.79%) 3,909(12.31%) 3,184(15.22%) 7,626(27.21%) 
 
3 or more 726 (4.87%) 565(7.75%) 1,550(4.88%) 1,223(5.85%) 3,206(11.44%) 
 
Diuretic Use 
Never 8,534 (58.47%) 5,750(79.05%) 26,831(84.30%) 15,996(80.41%) 23,737(84.22%) <.0001 
Past 2,271 (15.56%) 596(8.19%) 1,880(5.91%) 1,666(8.37%) 1,919(6.81%) 
 
Current 3,791 (25.97%) 928(12.76%) 3,118(9.80%) 2,231(11.22%) 2,530(8.98%) 
 
DASH Score mean(SD) 23.66 (4.33) 22.97(4.61) 23.29(4.48) 24.34(4.12) 25.40(4.25) <.0001 
DASH quintiles 
Q1 [8,20] 3,723 (24.95%) 2,250(30.87%) 8,897(28.01%) 3,920(18.74%) 3,728(13.30%) <.0001 
Q2 (20,23] 3,615 (24.23%) 1,623(22.27%) 7,661(24.12%) 4,869(23.27%) 5,312(18.95%) 
 
Q3 (23,25] 2,438 (16.34%) 1,124(15.42%) 5,064(15.94%) 3,760(17.97%) 4,830(17.23%) 
 
Q4 (25,28] 3,103 (20.80%) 1,457(19.99%) 5,994(18.87%) 5,033(24.06%) 7,371(26.30%) 
 
Q5 (28,40] 2,041 (13.68%) 835(11.46%) 4,151(13.07%) 3,340(15.96%) 6,786(24.21%) 
 
History of Hypertension No 7,380 (47.13%) 4,470(58.82%) 20,737(62.99%) 14,677(67.35%) 21,472(73.71%) <.0001 Yes 8,280 (52.87%) 3,130(41.18%) 12,185(37.01%) 7,115(32.65%) 7,657(26.29%) 
 
History of Heart Attack No 13,878 (88.62%) 7,075(93.09%) 31,196(94.76%) 19,982(91.69%) 27,270(93.62%) <.0001 Yes 1,782 (11.38%) 525(6.91%) 1,726(5.24%) 1,810(8.31%) 1,859(6.38%) 
 
History of Stroke No 15,072 (96.25%) 7,435(97.83%) 32,282(98.06%) 21,399(98.20%) 28,648(98.35%) <.0001 Yes 588 (3.75%) 165(2.17%) 640(1.94%) 393(1.80%) 481(1.65%) 
 
History of Diabetes No 13,437 (85.80%) 6,643(87.41%) 29,839(90.64%) 18,667(85.66%) 27,802(95.44%) <.0001 Yes 2,223 (14.20%) 957(12.59%) 3,083(9.36%) 3,125(14.34%) 1,327(4.56%) 
 
History of Kidney Stones No 15,259 (97.44%) 7,148(94.05%) 31,085(94.42%) 20,770(95.31%) 27,070(92.93%) <.0001 Yes 401 (2.56%) 452(5.95%) 1,837(5.58%) 1,022(4.69%) 2,059(7.07%) 
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Table 2. Baseline Characteristics by Sex and Ethnicity 
  Black Hawaiian Japanese Latino White 
  Female Male Female Male Female Male Female Male Female Male 
Baseline Age mean(SD) 60.37(8.97) 60.76(8.85) 56.35(8.07) 56.36(8.01) 60.16(8.65) 60.14(8.89) 58.53(7.32) 59.04(7.30) 58.60(8.76) 58.46(8.72) 
Education 
High School or Less 41.90% 39.69% 54.91% 48.03% 38.17% 33.07% 72.46% 64.22% 27.92% 20.34% 
Vocational/Some college 35.44% 35.80% 28.53% 31.76% 29.67% 30.30% 18.76% 22.46% 33.51% 29.06% 
Grad College/Grad School 22.66% 24.52% 16.56% 20.21% 32.16% 36.64% 8.78% 13.32% 38.57% 50.60% 
Generation US 
>1st gen 95.00% 94.48% 87.52% 87.86% 34.05% 35.79% 14.76% 13.86% 71.72% 73.47% 
1st gen 1.64% 1.85% 12.08% 11.83% 54.21% 59.08% 30.46% 30.80% 16.56% 16.43% 
immigrant 3.36% 3.67% 0.39% 0.31% 11.73% 5.12% 54.78% 55.34% 11.71% 10.11% 
Marital Status 
Married 33.61% 60.92% 64.33% 76.54% 73.61% 83.55% 52.98% 79.17% 62.02% 74.44% 
Separated/Divorced 35.53% 25.40% 16.48% 13.71% 8.77% 6.58% 23.33% 13.25% 20.81% 14.69% 
Widowed 24.18% 6.25% 14.46% 3.42% 11.39% 2.72% 14.47% 3.06% 11.75% 2.86% 
Never 6.68% 7.43% 4.73% 6.33% 6.23% 7.15% 9.22% 4.52% 5.42% 8.01% 
Body Mass Index 
<25 kg/m2 24.32% 30.24% 31.82% 21.95% 69.83% 50.48% 31.58% 24.90% 54.79% 38.25% 
25-30 kg/m2 38.10% 47.75% 33.85% 45.22% 23.89% 42.34% 40.03% 54.44% 28.18% 46.38% 
>30 kg/m2 37.58% 22.00% 34.33% 32.83% 6.29% 7.17% 28.40% 20.67% 17.03% 15.37% 
Smoking Status 
Never 45.80% 25.91% 44.58% 32.39% 68.92% 31.39% 64.36% 32.71% 45.70% 32.72% 
Past 34.61% 47.19% 32.44% 45.47% 22.27% 54.20% 25.09% 49.18% 38.66% 51.31% 
Current 19.60% 26.90% 22.98% 22.14% 8.81% 14.41% 10.54% 18.11% 15.65% 15.97% 
Vitamin C Supplementation No 57.02% 62.33% 67.16% 72.32% 56.34% 61.60% 61.53% 67.70% 53.68% 58.50% Yes 42.98% 37.67% 32.84% 27.68% 43.66% 38.40% 38.47% 32.30% 46.32% 41.50% 
METs mean(SD) 1.57(0.27) 1.63(0.32) 1.61(0.32) 1.72(0.38) 1.58(0.24) 1.64(0.29) 1.63(0.28) 1.73(0.36) 1.60(0.27) 1.66(0.33) 
# of Alcoholic Drinks/Day 
None 88.13% 69.53% 86.09% 61.48% 94.42% 67.43% 91.25% 64.68% 69.91% 50.62% 
1 to 2 9.43% 20.87% 11.02% 23.20% 4.92% 22.09% 7.33% 24.36% 23.80% 31.48% 
3 or more 2.43% 9.60% 2.89% 15.32% 0.66% 10.48% 1.43% 10.97% 6.29% 17.90% 
Diuretic Use 
Never 53.72% 67.72% 76.46% 83.06% 83.62% 85.18% 76.45% 84.89% 80.71% 88.60% 
Past 17.45% 11.88% 9.41% 6.31% 6.05% 5.72% 9.98% 6.56% 8.48% 4.72% 
Current 28.83% 20.40% 14.13% 10.63% 10.33% 9.10% 13.56% 8.56% 10.82% 6.68% 
DASH Score mean(SD) 23.59(4.34) 23.79(4.30) 23.03(4.60) 22.89(4.63) 23.46(4.40) 23.07(4.57) 24.30(4.17) 24.39(4.05) 25.36(4.23) 25.45(4.28) 
DASH quintiles 
Q1 [8,20] 25.88% 23.14% 30.21% 31.90% 25.84% 30.88% 19.51% 17.84% 13.07% 13.60% 
Q2 (20,23] 23.38% 25.89% 22.11% 22.50% 24.69% 23.36% 22.46% 24.21% 19.65% 18.08% 
Q3 (23,25] 16.28% 16.46% 15.49% 15.32% 16.78% 14.83% 18.02% 17.92% 17.31% 17.13% 
Q4 (25,28] 21.29% 19.84% 20.54% 19.14% 19.37% 18.21% 23.85% 24.29% 26.33% 26.27% 
Q5 (28,40] 13.17% 14.66% 11.65% 11.15% 13.32% 12.73% 16.16% 15.74% 23.64% 24.92% 
History of Hypertension No 46.08% 49.19% 58.97% 58.57% 65.10% 60.18% 65.67% 69.30% 74.36% 72.90% Yes 53.92% 50.81% 41.03% 41.43% 34.90% 39.82% 34.33% 30.70% 25.64% 27.10% 
History of Heart Attack No 88.40% 89.05% 94.08% 91.55% 97.02% 91.76% 92.10% 91.22% 95.40% 91.38% Yes 11.60% 10.95% 5.92% 8.45% 2.98% 8.24% 7.90% 8.78% 4.60% 8.62% 
History of Stroke No 96.14% 96.45% 97.69% 98.05% 98.58% 97.36% 98.38% 97.99% 98.47% 98.20% Yes 3.86% 3.55% 2.31% 1.95% 1.42% 2.64% 1.62% 2.01% 1.53% 1.80% 
History of Diabetes No 85.95% 85.52% 87.86% 86.70% 91.59% 89.36% 85.87% 85.42% 95.71% 95.11% Yes 14.05% 14.48% 12.14% 13.30% 8.41% 10.64% 14.13% 14.58% 4.29% 4.89% 
History of Kidney Stones No 97.97% 96.41% 95.14% 92.35% 97.07% 90.90% 96.61% 93.80% 95.97% 89.13% Yes 2.03% 3.59% 4.86% 7.65% 2.93% 9.10% 3.39% 6.20% 4.03% 10.87% 
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Table 3. Ethnic-Stratified Hazard Ratios and 95% Confidence Intervals for Modifiable Lifestyle Factors 
  Black  (N=15,660) 
Hawaiian  
(N=7,600) 
Japanese  
(N=32,923) 
Latino  
(N=21,793) 
White  
(N=29,129) 
Total 
(N=107,105) 
Past Smoking 
(ref. Never) 
Crude 1.13 (1.02, 1.24) *   1.07 (0.95, 1.21)    1.57 (1.47, 1.68) *** 1.14 (1.03, 1.27) **  1.21 (1.12, 1.32) *** 1.29 (1.24, 1.34) *** 
Model 1 1.13 (1.02, 1.25) * 1.00 (0.88, 1.13) 1.15 (1.07, 1.24) *** 1.12 (1.01, 1.26) * 1.14 (1.05, 1.24) ** 1.14 (1.09, 1.19) *** 
Model 2‡ 1.06 (0.94, 1.19) 0.93 (0.82, 1.06) 1.03 (0.94, 1.11) 1.04 (0.92, 1.18) 1.07 (0.98, 1.18) 1.05 (1.01, 1.10) * 
Model 3 1.04 (0.92, 1.17)    0.91 (0.79, 1.04)    1.00 (0.92, 1.09) 1.02 (0.90, 1.16) 1.08 (0.98, 1.19) 1.04 (1.00, 1.09) 
Current Smoking 
(ref. Never) 
Crude 1.33 (1.17, 1.51) *** 1.13 (0.97, 1.31)    1.67 (1.50, 1.86) *** 1.12 (0.96, 1.31)    1.13 (1.00, 1.28) 1.38 (1.30, 1.46) *** 
Model 1 1.33 (1.18, 1.52) *** 1.10 (0.94, 1.28) 1.26 (1.13, 1.41) *** 1.09 (0.93, 1.28) 1.11 (0.97, 1.26) 1.22 (1.15, 1.29) *** 
Model 2‡ 1.28 (1.10, 1.49) ** 1.15 (0.97, 1.36) 1.17 (1.03, 1.32) * 1.03 (0.86, 1.24) 1.09 (0.95, 1.26) 1.18 (1.11, 1.26) *** 
Model 3 1.30 (1.11, 1.51) **  1.14 (0.96, 1.35)    1.16 (1.02, 1.31) * 0.98 (0.81, 1.19) 1.09 (0.95, 1.26) 1.17 (1.10, 1.25) *** 
Vitamin C Use 
(ref. No Use) 
Crude 1.00 (0.91, 1.10)    0.78 (0.69, 0.89) *** 0.82 (0.77, 0.88) *** 0.89 (0.81, 0.99) *   0.92 (0.85, 0.99) *   0.86 (0.83, 0.90) *** 
Model 1 1.00 (0.91, 1.10) 0.81 (0.71, 0.92) ** 0.86 (0.81, 0.92) *** 0.88 (0.79, 0.98) * 0.93 (0.86, 1.01) 0.89 (0.86, 0.93) *** 
Model 2‡ 1.02 (0.92, 1.14) 0.85 (0.75, 0.98) * 0.91 (0.85, 0.98) * 0.99 (0.88, 1.11) 1.09 (0.94, 1.26) 0.97 (0.93, 1.01) 
Model 3 1.03 (0.92, 1.16) 0.85 (0.74, 0.98) * 0.91 (0.85, 0.98) * 0.95 (0.84, 1.08) 1.08 (0.93, 1.26) 0.96 (0.92, 1.00) 
MET Score 
Crude 0.81 (0.68, 0.97) *   0.98 (0.82, 1.16)    0.96 (0.84, 1.09)    0.69 (0.58, 0.82) *** 0.92 (0.80, 1.06)    0.87 (0.81, 0.94) *** 
Model 1 0.82 (0.68, 0.99) * 0.87 (0.73, 1.03) 0.91 (0.80, 1.03) 0.70 (0.58, 0.84) *** 0.83 (0.74, 0.99) * 0.83 (0.78, 0.89) *** 
Model 2‡ 1.05 (0.86, 1.28) 1.04 (0.87, 1.24) 0.97 (0.84, 1.11) 0.77 (0.64, 0.93) ** 1.10 (0.95, 1.27) 1.00 (0.93, 1.08) 
Model 3 1.04 (0.84, 1.28) 1.05 (0.87, 1.26) 0.97 (0.85, 1.12) 0.78 (0.64, 0.94) * 1.09 (0.94, 1.26) 1.00 (0.93, 1.08) 
1 to 2 Alcoholic 
Drinks per Day 
(ref. None) 
Crude 1.15 (1.01, 1.32) *   1.10 (0.95, 1.28)    1.61 (1.48, 1.76) *** 1.07 (0.94, 1.23)    1.03 (0.94, 1.13)    1.16 (1.11, 1.22) *** 
Model 1 1.15 (1.00, 1.32) * 0.96 (0.82, 1.12) 1.18 (1.08, 1.30) *** 1.04 (0.90, 1.20) 0.97 (0.89, 1.07) 1.07 (1.01, 1.12) * 
Model 2‡ 1.20 (1.03, 1.40) * 1.07 (0.90, 1.26) 1.21 (1.09, 1.34) *** 1.09 (0.93, 1.27) 1.04 (0.94, 1.15) 1.12 (1.06, 1.19) *** 
Model 3 1.20 (1.03, 1.41) * 1.07 (0.90, 1.27) 1.22 (1.10, 1.35) *** 1.06 (0.90, 1.24) 1.03 (0.94, 1.15) 1.12 (1.06, 1.19) *** 
3+ Alcoholic 
Drinks per Day 
(ref. None) 
Crude 1.45 (1.19, 1.77) *** 1.58 (1.32, 1.89) *** 2.27 (2.01, 2.56) *** 1.21 (0.99, 1.48) 1.52 (1.37, 1.70) *** 1.61 (1.51, 1.72) *** 
Model 1 1.44 (1.18, 1.77) *** 1.22 (1.01, 1.48) * 1.52 (1.34, 1.73) *** 1.18 (0.95, 1.45) 1.34 (1.20, 1.50) *** 1.38 (1.29, 1.48) *** 
Model 2‡ 1.55 (1.23, 1.94) *** 1.34 (1.09, 1.64) ** 1.47 (1.28, 1.69) *** 1.16 (0.93, 1.45) 1.33 (1.18, 1.51) *** 1.39 (1.29, 1.49) *** 
Model 3 1.46 (1.14, 1.85) ** 1.42 (1.15, 1.75) *** 1.54 (1.34, 1.77) *** 1.20 (0.95, 1.52) 1.35 (1.19, 1.53) *** 1.42 (1.32, 1.52) *** 
DASH Tertile 2 
[22-26] 
(ref. Tertile 1) 
Crude 0.82 (0.73, 0.91) *** 0.81 (0.72, 0.92) ** 0.73 (0.68, 0.79) *** 0.89 (0.79, 1.00) 0.77 (0.69, 0.85) *** 0.77 (0.73, 0.80) *** 
Model 1† 0.83 (0.74, 0.92) *** 0.84 (0.74, 0.96) ** 0.81 (0.75, 0.87) *** 0.90 (0.79, 1.01) 0.76 (0.69, 0.84) *** 0.80 (0.76, 0.84) *** 
Model 2‡ 0.85 (0.75, 0.97) * 0.86 (0.75, 0.98) * 0.83 (0.76, 0.90) *** 0.91 (0.80, 1.04) 0.77 (0.69, 0.85) *** 0.82 (0.78, 0.86) *** 
Model 3 0.84 (0.74, 0.95) ** 0.87 (0.75, 1.00) * 0.84 (0.77, 0.91) *** 0.90 (0.78, 1.03) 0.77 (0.69, 0.85) *** 0.83 (0.79, 0.87) *** 
DASH Tertile 3 
[26-40] 
(ref. Tertile 1) 
Crude 0.75 (0.67, 0.83) *** 0.70 (0.61, 0.80) *** 0.65 (0.60, 0.70) *** 0.89 (0.79, 1.00) * 0.64 (0.58, 0.71) *** 0.68 (0.65, 0.71) *** 
Model 1† 0.74 (0.66, 0.83) *** 0.72 (0.62, 0.83) *** 0.73 (0.67, 0.79) *** 0.89 (0.79, 1.01) 0.65 (0.58, 0.71) *** 0.71 (0.67, 0.74) *** 
Model 2‡ 0.81 (0.70, 0.93) ** 0.80 (0.69, 0.93) ** 0.77 (0.70, 0.85) *** 0.90 (0.78, 1.03) 0.70 (0.63, 0.78) *** 0.76 (0.72, 0.80) *** 
Model 3 0.80 (0.69, 0.91) ** 0.80 (0.68, 0.93) ** 0.78 (0.71, 0.86) *** 0.90 (0.78, 1.03) 0.69 (0.62, 0.77) *** 0.76 (0.72, 0.81) *** 
Model 1 (Total Effects Model) is adjusted for sex, education level, generation in the United States, and marital status. †In addition, Model 1 is adjusted for number of alcoholic drinks per day for the total effects of DASH tertiles. 
‡Model 2 is adjusted for the minimum sufficient adjustment set for the direct effect of each covariate as determined by directed acyclic graphs; in Model 2 the effects of: 
 Smoking Status is adjusted for sex (male/female), BMI (continuous), education level, generation in the United States, marital status, history of cardiovascular disease (hypertension, heart attack, angina, and stroke (yes/no)),  
 history of kidney stones (yes/no), total DASH score (continuous), number of alcoholic drinks per day, and physical activity (METs Score, continuous). 
 Vitamin C Use is adjusted for sex (male/female), BMI (continuous), education level, generation in the United States, total DASH score (continuous), number of alcoholic drinks per day, and smoking status. 
 MET Score is adjusted for sex (male/female), BMI (continuous), education level, generation in the United States, marital status, history of cardiovascular disease, history of kidney stones, total DASH score, number of  
 alcoholic drinks per day, and smoking status. 
 Alcoholic Drinks is adjusted for sex (male/female), BMI (continuous), education level, generation in the United States, marital status, history of cardiovascular disease, history of kidney stones, total DASH score, physical  
 activity, and smoking status. 
 DASH Score is adjusted for sex (male/female), BMI (continuous), education level, generation in the United States, marital status, history of cardiovascular disease, history of kidney stones, number of alcoholic drinks per  
 day, physical activity, and smoking status. 
Model 3 is adjusted for all covariates. 
Acronyms: BMI = Body Mass Index, MET = Metabolic Equivalent, DASH = Dietary Approaches to Stop Hypertension 
MET = [(# Hours Sleeping × 0.91) + (# Hours Sitting × 1.0) + (# Hours in Light Activities × 2.4) + (# Hours in Moderate Activity × 4.0) + (# Hours in Vigorous Activity × 7.2)] / 24 
*p<0.05, **p<0.01, ***p<0.001 
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Table 4. Study 2 Subsample Baseline Characteristics by Gout Cumulative Incidence (N=6,567) 
  Gout No Gout p-value 
Ethnicity 
Black 125 (11.43%) 969 (88.57%) <.0001 
Hawaiian 171 (13.98%) 1,052 (86.02%) 
 
Japanese 151 (9.10%) 1,508 (90.90%) 
 
Latino 135 (6.29%) 2,011 (93.71%) 
 
White 37 (8.31%) 408 (91.69%) 
 
Sex Female 344 (11.54%) 2,638 (88.46%) <.0001 Male 275 (7.67%) 3,310 (92.33%) 
 
Age at Blood Draw Mean ± SD 68.71 ± 7.37 67.52 ± 7.74 0.0003 Median (Q1, Q3) 68.18 (62.80, 74.21) 66.76 (61.64, 73.31) 
 
Education Level at 
Baseline 
High School or Less 227 (9.07%) 2,275 (90.93%) 0.2953 
Some College/Vocational 188 (9.10%) 1,877 (90.90%) 
 
Grad College/Professional 201 (10.32%) 1,746 (89.68%) 
 
Place of Birth US born 538 (10.23%) 4,720 (89.77%) <.0001 Foreign Born 79 (6.11%) 1,213 (93.89%) 
 
Marital Status Married 441 (9.58%) 4,164 (90.42%) 0.5013 Not Married 172 (9.01%) 1,738 (90.99%) 
 
Body Mass Index 
< 25 kg/m2 169 (6.48%) 2,440 (93.52%) <.0001 
25 – 30 kg/m2 281 (10.43%) 2,412 (89.57%) 
 
> 30 kg/m2 167 (13.48%) 1,072 (86.52%) 
 
Smoking Status 
Never 262 (8.45%) 2,839 (91.55%) 0.0158 
Past 264 (10.28%) 2,304 (89.72%) 
 
Current 89 (11.14%) 710 (88.86%) 
 
Vitamin C 
Supplementation 
No 383 (9.93%) 3,475 (90.07%) 0.2879 
Yes 221 (9.08%) 2,212 (90.92%) 
 
Physical Activity 
(MET) 
Mean ± SD 1.62 ± 0.29 1.63 ± 0.31 0.2745 
Median (Q1, Q3) 1.61 (1.43,1.79) 1.62 (1.42,1.79) 
 
Number of Drinks per 
Day 
None 418 (8.55%) 4,472 (91.45%) 0.0001 
1 to 2 131 (11.93%) 967 (88.07%) 
 
3 or More 53 (12.71%) 364 (87.29%) 
 
Diuretic Use 
Never 424 (8.34%) 4,659 (91.66%) <.0001 
Past 63 (12.45%) 443 (87.55%) 
 
Current 107 (15.55%) 581 (84.45%) 
 
DASH Score Mean (SD) 23.80 (4.34) 24.07 (4.34) 0.1437 Median (Q1, Q3) 24 (21, 27) 24 (21, 27) 
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Table 5. Biomarker Summary by Gout Cumulative Incidence 
  Gout No Gout p-value† 
C-Reactive Protein 
mg/L 
Mean ± SD 3.53 ± 4.38 3.01 ± 3.89 0.002 
Tertile 1 199 (8.26%) 2,209 (91.74%) 
 
Tertile 2 175 (8.86%) 1,800 (91.14%) 
 
Tertile 3 245 (11.25%) 1,932 (88.75%) 
 
Total Cholesterol 
mg/dL 
Mean ± SD 189.27 ± 40.20 195.12 ± 39.73 0.005 
Tertile 1 248 (11.35%) 1,937 (88.65%) 
 
Tertile 2 192 (8.79%) 1,993 (91.21%) 
 
Tertile 3 177 (8.10%) 2,007 (91.90%) 
 
HDL-Cholesterol 
mg/dL 
Mean ± SD 43.41 ± 14.80 46.31 ± 16.07 <.0001 
Tertile 1 261 (11.19%) 2,071 (88.81%) 
 
Tertile 2 198 (9.60%) 1,864 (90.40%) 
 
Tertile 3 158 (7.34%) 1,994 (92.66%) 
 
LDL-Cholesterol 
mg/dL 
Mean ± SD 120.23 ± 37.65 124.59 ± 37.00 0.0057 
Tertile 1 231 (10.64%) 1,940 (89.36%) 
 
Tertile 2 207 (9.57%) 1,957 (90.43%) 
 
Tertile 3 173 (7.98%) 1,994 (92.02%) 
 
Triglycerides 
mg/dL 
Mean ± SD 131.27 ± 81.33 123.45 ± 81.56 0.0232 
Tertile 1 185 (8.33%) 2,036 (91.67%) 
 
Tertile 2 198 (9.12%) 1,973 (90.88%) 
 
Tertile 3  235 (10.85%) 1,931 (89.15%) 
 
α-Tocopherol 
mg/L 
Mean ± SD 9.54 ± 4.73 9.97 ± 5.09 0.074 
Tertile 1 182 (11.60%) 1,387 (88.40%) 
 
Tertile 2 169 (10.78%) 1,399 (89.22%) 
 
Tertile 3 149 (9.50%) 1,420 (90.50%) 
 
γ-Tocopherol 
mg/L  
Mean ± SD 2.02 ± 1.11 1.88 ± 1.53 0.0649 
Tertile 1 140 (8.93%) 1,428 (91.07%) 
 
Tertile 2 161 (10.27%) 1,407 (89.73%) 
 
Tertile 3 199 (12.69%) 1,369 (87.31%) 
 
α-Carotene 
ng/mL 
Mean ± SD 72.47 ± 71.30 85.66 ± 93.67 0.0023 
Tertile 1 213 (13.58%) 1,356 (86.42%) 
 
Tertile 2 159 (10.14%) 1,409 (89.86%) 
 
Tertile 3 128 (8.16%) 1,441 (91.84%) 
 
β-Carotene 
ng/mL 
Mean ± SD 277.32 ± 254.66 355.52 ± 402.96 <.0001 
Tertile 1 216 (13.77%) 1,353 (86.23%) 
 
Tertile 2 153 (9.76%) 1,415 (90.24%) 
 
Tertile 3 131 (8.35%) 1,438 (91.65%) 
 
Adiponectin 
μg/mL 
Mean ± SD 7.66 ± 5.39 8.46 ± 5.77 0.001 
Tertile 1 247 (11.34%) 1,932 (88.66%) 
 
Tertile 2 194 (8.91%) 1,984 (91.09%) 
 
Tertile 3 177 (8.13%) 2,001 (91.87%) 
 
Leptin 
mg/L 
Mean ± SD 23.18 ± 24.15 19.08 ± 19.52 <.0001 
Tertile 1 183 (8.36%) 2,005 (91.64%) 
 
Tertile 2 204 (9.33%) 1,983 (90.67%) 
 
Tertile 3 232 (10.61%) 1,955 (89.39%) 
 
†p-values based on bivariate Student T-Test for mean differences 
Acronyms: SD = standard deviation, LDL = low-density lipoprotein, HDL = high-density lipoprotein 
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Table 6. 
  Tertiles of Serum Biomolecule Concentrations 
Biomolecule  1 2 3 
C-reactive Protein 
mg/L 
Range [0, 1.0] (1.0, 2.8] (2.8, 21.0] 
Crude, HR (95% CI) ref 1.02 (0.83, 1.24) 1.42 (1.18, 1.71) *** 
Model 1, HR (95% CI) ref 1.21 (0.98, 1.49) 1.84 (1.51, 2.25) *** 
Model 2, HR (95% CI) ref 1.14 (0.91, 1.42) 1.48 (1.18, 1.87) *** 
Total Cholesterol 
mg/dL 
Range [42.3, 176] (176, 210] (210, 405] 
Crude, HR (95% CI) ref 0.82 (0.68, 0.99) * 0.78 (0.65, 0.95) * 
Model 1, HR (95% CI) ref 0.85 (0.70, 1.02) 0.84 (0.69, 1.03) 
Model 2, HR (95% CI) ref 0.88 (0.71, 1.08) 1.00 (0.80, 1.24) 
LDL-Cholesterol 
mg/dL 
Range [10.2, 108] (108, 138] (138, 364] 
Crude, HR (95% CI) ref 0.97 (0.80, 1.17) 0.84 (0.69, 1.03) 
Model 1, HR (95% CI) ref 0.93 (0.77, 1.13) 0.80 (0.65, 0.98) * 
Model 2, HR (95% CI) ref 1.00 (0.81, 1.23) 0.91 (0.72, 1.13) 
HDL-Cholesterol 
mg/dL 
Range [4.0, 38] (38, 50] (50, 205] 
Crude, HR (95% CI) ref 0.83 (0.69, 1.00) * 0.57 (0.47, 0.70) *** 
Model 1, HR (95% CI) ref 0.86 (0.71, 1.04) 0.62 (0.51, 0.77) *** 
Model 2, HR (95% CI) ref 0.97 (0.79, 1.19) 0.74 (0.59, 0.94) * 
Triglycerides 
mg/dL 
Range [12.0, 83] (83, 131] (131, 1000] 
Crude, HR (95% CI) ref 1.18 (0.96, 1.44) 1.48 (1.22, 1.79) *** 
Model 1, HR (95% CI) ref 1.34 (1.10, 1.65) ** 1.83 (1.50, 2.23) *** 
Model 2, HR (95% CI) ref 1.27 (1.02, 1.59) * 1.54 (1.23, 1.92) *** 
α-Tocopherol 
mg/L 
Range [0, 7.32] (7.32, 10.60] (10.60, 124.00] 
Crude, HR (95% CI) ref 0.81 (0.66, 1.00) 0.65 (0.52, 0.81) *** 
Model 1, HR (95% CI) ref 0.93 (0.75, 1.15) 0.84 (0.67, 1.05) 
Model 2, HR (95% CI) ref 0.95 (0.75, 1.20) 0.92 (0.72, 1.19) 
γ-Tocopherol 
mg/L 
Range [0.268, 1.32] (1.32, 2.04] (2.04, 46.70] 
Crude, HR (95% CI) ref 1.24 (0.99, 1.55) 1.74 (1.40, 2.16) *** 
Model 1, HR (95% CI) ref 1.17 (0.93, 1.47) 1.69 (1.35, 2.11) *** 
Model 2, HR (95% CI) ref 1.07 (0.83, 1.37) 1.47 (1.15, 1.89) ** 
α-Carotene 
ng/mL 
Range [0, 45.5] (45.5, 87.2] (87.2, 3170] 
Crude, HR (95% CI) ref 0.67 (0.54, 0.82) *** 0.51 (0.41, 0.64) *** 
Model 1, HR (95% CI) ref 0.68 (0.55, 0.84) *** 0.56 (0.44, 0.70) *** 
Model 2, HR (95% CI) ref 0.75 (0.59, 0.95) * 0.76 (0.58, 0.98) * 
β-Carotene 
ng/mL 
Range [0, 169] (169, 352] (352, 11300] 
Crude, HR (95% CI) ref 0.60 (0.48, 0.73) *** 0.46 (0.37, 0.57) *** 
Model 1, HR (95% CI) ref 0.62 (0.50, 0.76) *** 0.52 (0.41, 0.66) *** 
Model 2, HR (95% CI) ref 0.70 (0.56, 0.89) ** 0.72 (0.55, 0.94) ** 
Adiponectin 
μg/mL 
Range [0, 5.06] (5.06, 9.05] (9.05, 26.5] 
Crude, HR (95% CI) ref 0.69 (0.57, 0.83) *** 0.54 (0.45, 0.66) *** 
Model 1, HR (95% CI) ref 0.76 (0.63, 0.92) ** 0.67 (0.54, 0.82) *** 
Model 2, HR (95% CI) ref 0.81 (0.66, 1.00) * 0.73 (0.58, 0.92) ** 
Leptin 
mg/L 
Range [0, 7.68] (7.68, 20.60] (20.60, 106.00] 
Crude, HR (95% CI) ref 1.19 (0.97, 1.45) 1.50 (1.24, 1.83) *** 
Model 1, HR (95% CI) ref 1.55 (1.26, 1.91) *** 2.73 (2.14, 3.47) *** 
Model 2, HR (95% CI) ref 1.36 (1.07, 1.71) * 2.09 (1.56, 2.81) *** 
Model 1 adjusted for sex and ethnicity 
Model 2 adjusted for strata(sex), ethnicity, education level, place of birth, and other baseline characteristics (body mass index, marital status, smoking status, vitamin C 
supplementation, physical activity level, number of alcoholic drinks per day, history of diuretic use, and strata(tertiles of DASH diet adherence score) 
Acronyms: HR = hazard ratio from cox proportional hazard model, CI = confidence interval, ref = reference group, LDL = low-density lipoprotein, HDL = high-density 
lipoprotein 
All models pass the proportional hazards assumption 
*p<0.05, **p<0.01, ***p<0.001 
 
 
 
